Document:

ADBE EX 10.52 FY14

EXHIBIT 10.52

ADOBE SYSTEMS INCORPORATED 
FY ‘15 NON-EMPLOYEE DIRECTOR COMPENSATION POLICY 

(Effective First Day of FY 2015) 
Cash Compensation 
Board Member Annual Retainer 
		
	• 
	$60,000 annual fee 

Board Chair Annual Retainer 
		
	• 
	$50,000 annual fee for each Chair 

Committee Member Annual Retainers  
•Audit Committee – $20,000 annual fee 
•Executive Compensation Committee – $15,000 annual fee 
•Nominating and Governance Committee – $7,500 annual fee 

Committee Chair Retainers 
•Audit Committee – $40,000 annual fee 
•Executive Compensation Committee – $30,000 annual fee 
•Nominating and Governance Committee – $15,000 annual fee 

The annual retainers described above for Board Chair, Committee Member and Committee Chair service are in addition to the base $60,000 Board Member annual retainer.  A Committee Chair receives the Chair retainer for the applicable Committee, but does not also receive the Committee Member Annual Retainer.  All cash compensation is earned on a fiscal year basis, paid at the end of each quarter.  Directors who commence service mid-quarter or who terminate service mid-quarter will receive pro-rated retainers to be paid at the end of the applicable quarter.
Each Director may elect to defer 5% to 100% of cash compensation in the Adobe Deferred Compensation Plan by timely submitting an election to the company. 
Equity Compensation
New Director Restricted Stock Unit Award 
A restricted stock unit award will be granted to each new Director on the date that the new Director is appointed to the Board of Directors based on the following conditions: 
    
		
	•
	The award will be based upon a maximum target grant value of $260,000 

		
	•
	The actual target grant value will be calculating by pro-rating the $260,000 maximum target grant value based on the number of calendar days remaining before (1) the next 

Annual Meeting of Shareholders, if scheduled, or (2) the date of the first anniversary of our last Annual Meeting of Shareholders, if the next Annual Meeting of Shareholders is not yet scheduled 
		
	•
	The actual target grant value (as calculated directly above) shall be converted into the number of shares underlying the award based on the average closing stock price over the 30 calendar days ending on the day before the date of grant (rounded down to the next whole share)  

		
	•
	The award will vest 100% on the day immediately preceding the date of our next Annual Meeting of Stockholders

		
	•
	If the pro-rated actual target grant value of the award is less than $10,000, no equity grant shall be made to the new Director

Annual Restricted Stock Unit Award 
An annual restricted stock unit award will be granted to each Director on the business day immediately following the date of our Annual Meeting of Stockholders based on the following conditions: 

		
	•
	The award shall have a target grant value of $260,000 

		
	•
	The target grant value shall be converted into the number of shares underlying the award based on the average closing stock price of Adobe common stock over the 30 calendar days ending on the day before the date of grant (rounded down to the next whole share) 

		
	•
	The award will vest 100% on the day immediately preceding the date of our next Annual Meeting of Stockholders  

Each Director may elect to defer either 0% or 100% (per vesting tranche) of restricted stock unit awards in the Adobe Deferred Compensation Plan by timely submitting an election. 
All equity grants are subject to our Stock Ownership Guidelines. 
This policy will be reviewed annually.Exhibit 10.2 Conflict of Interest Agreement

EXHIBIT 10.2

CONFLICT OF INTEREST AGREEMENT 

AGREEMENT dated this 19th day of January 2015, by and between Remove-By-You, Inc. (hereinafter “Remove-By-You”), a Nevada corporation, with offices located at 128 Walnut Hill Road, Bethel, CT 06801 and Kyle Markward, President of Remove-By-You.

The parties hereto agree and acknowledge that by virtue of Kyle Markward’s other business activities as described in Remove-By-You’ Form S-1 Registration Statement, certain potential conflicts of interest may arise.

In an effort to resolve such potential conflicts of interest, we have entered into this written agreement with Kyle Markward:

·

any business opportunities that Kyle Markward may become aware of independently or directly through his association with us would be presented by him solely to us;

·

any business opportunities disclosed to Kyle Markward by the management of other entities would not be presented by him to us if so requested by them;

·

any business opportunities disclosed to Kyle Markward by us would not be presented by him to any other entity, unless and until we passed upon same; and

·

in the event that the same business opportunity is presented to Kyle Markward by both us and any other business entity, he shall only render his services to the business entity that first disclosed such business opportunity to her.

The above constitutes the entire Agreement between the parties hereto.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the 19th day of January 2015.

	
	REMOVE-BY-YOU, INC.

	 

	 

	By: /s/ Kyle Markward

	Kyle Markward, President

	 

	 

	By: /s/ Kyle Markward

	Kyle Markward, IndividuallyCONFIDENTIAL
TREATMENT REQUESTED. Confidential portions of this document have been redacted and have been separately filed with the Commission.

 

Exhibit No.
10.1

 

 

 

 

LICENSING
AGREEMENT 

 

BY
AND BETWEEN

 

TG
THERAPEUTICS, INC.

 

AND

 

RHIZEN
PHARMACEUTICALS S A

 

 

    	Confidential	Page 1	 

    	 

    

 

This Licensing
Agreement is made and entered into on 22 September 2014 (the “Effective Date”) by and between

 

Rhizen Pharmaceuticals
S.A., a Swiss corporation having its principal place of business at Fritz Courvoisier 40, 2300 La Chaux de Fonds, Switzerland
(“Rhizen”),

 

On the one hand,

 

And

TG Therapeutics,
Inc., a Delaware corporation, with a place of business at 787 Seventh Avenue, New York, NY (“TGTX”).

 

On the other
hand;

 

WITNESSETH:

WHEREAS,
Rhizen is a pharmaceutical company focused on the development of novel inhibitors of PI3Kδ for the treatment of various
B-cell proliferative diseases;

 

WHEREAS,
TGTX is a biopharmaceutical company engaged in the development, manufacturing and marketing of pharmaceutical products directed
toward the treatment of B-cell proliferative diseases;

 

WHEREAS,
Rhizen and TGTX are parties to that certain Joint Venture and License Option Agreement, dated 15th August , 2012
( the “JV Agreement”).

 

WHEREAS,
The development of the Product has, to date, progressed satisfactorily to each Party to the JV Agreement, and each Party has
upheld the responsibilities delegated to such Party dictated in the JV Agreement;

 

WHEREAS,
The JV Agreement affords TGTX the option to license the exclusive rights to the Product under the terms of Article 6.2 and
Exhibit F of such JV Agreement;

 

WHEREAS,
In the interest of continued accelerated development of the Product, TGTX wishes to execute such license option outside of
the terms dictated in Article 6.2 and Exhibit F of such JV Agreement, and Rhizen is in agreement with such early execution
of the option granted to TGTX

 

WHEREAS,
With reference to Article 15.1 of the JV Agreement and pursuant to the promising progress of RP5264 (now TGR-1202) and recent
discussion between the parties, each of TGTX and Rhizen hereby wishes to execute this Licensing Agreement.

 

WHEREAS,
TGTX pursuant to the JV Agreement wishes to exercise its option to in license to TGTX all the proprietary rights in and to
the compound known as “RP5264” or any one of the back-up compounds; and Rhizen agrees to out license to such compound
known as “RP5264” or any one of the back-up compounds in order to develop, manufacture and commercialize Products
(as hereinafter defined); and

 

WHEREAS,
both TGTX and Rhizen, pursuant to the JV Agreement wish to enter into this definitive Agreement which provides
TGTX with an exclusive license to the Compound (as hereinafter defined) to develop and commercialize Products (as hereinafter
defined) in the Field of Use (as hereinafter defined) and in the Territory (as hereinafter defined), under the terms and conditions
set forth below;

  

    	2

    	 

    

 

NOW, THEREFORE,
in consideration of the foregoing and the covenants and obligations set forth herein, including the exhibits or appendices
hereto, and intending to be legally bound , TGTX and Rhizen hereby agree as follows:

 

1. DEFINITIONS
AND INTERPRETATIONS

 

Terms, when
used with initial capital letters, shall have the meanings set forth below or at their first use when used in this Agreement:

 

“Active
Commercialization”: solely for purposes of Section 3.1.3 hereof, shall mean TGTX is employing the level of efforts and
resources to Commercialize the Product in a Major Market in a sustained manner that is consistent with the efforts and resources
a biopharmaceutical company typically devotes to a product that is commercially viable.

 

“Active
Clinical Development”: solely for purposes of Section 3.1.3 hereof, shall mean TGTX is employing the level of efforts
and resources to achieve Regulatory Approval of a Product in a Major Market in a sustained manner that is consistent with the
efforts and resources a biopharmaceutical company typically devotes to a product that it has determined has positive market potential,
profit potential, and strategic value. If a notice is required to be delivered by TGTX to Rhizen pursuant to Section 3.2.4 hereof,
then the Compound shall no longer be considered to be in Active Clinical Development. Once the first Regulatory Approval for a
Product in a Major Market is achieved, the Compound may no longer be considered to be in Active Clinical Development for purposes
of Section 3.1.3.

 

“Agreement”:
shall mean this License Agreement

 

“API”:
shall mean an active pharmaceutical ingredient.

 

“Backup
Compound” means any * compounds other than RP5264 as provided in
Annexure VI Controlled by Rhizen as of the Effective Date and/or developed during the Term, which (i) falls within the chemical
genus provided in Exhibit B of the JV Agreement, and (ii) has targeted * (≤ *) in an * against the * target and targeted
specificity of * compared to the *. The initial list of the Backup Compounds is attached hereto as Annexure VI and shall be updated
from time to time by Rhizen and provided to TGTX promptly. The list of the Backup Compounds thus updated shall include any compound
which falls in the above definition which are discovered or developed by Rhizen during the first two years of the Term.

 

“Bulk
API” shall mean any of the Compounds in bulk form.

 

“Cause”
means, for purposes of Section 12.1, any unfavorable result from a pre-clinical or clinical trial that, as reasonably determined
by TGTX, causes material concerns regarding the tolerability, safety or effectiveness of the Product.

 

“Change
of Control”: means (i) the acquisition, directly or indirectly, by any person, entity or “group” (within
meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended) by means of a transaction or series
of related transactions, of (a) beneficial ownership of fifty percent (50%) or more of the outstanding voting securities of a
Party (or the surviving entity, as applicable, whether by merger, consolidation, reorganization, tender offer or other similar
means), or (b) all, or substantially all, of the assets of a Party; or (ii) any consolidation or merger of a Party with or into
any Third Party, or any other corporate reorganization involving a Third Party, in which those persons or entities that are stockholders
of the Party immediately prior to such consolidation, merger or reorganization (or prior to any series of related transactions
leading up to such event) own fifty (50%) or less of the surviving entity’s voting power immediately after such consolidation,
merger or reorganization.

  

 

*
Confidential material redacted and filed separately with the Commission.

 

    	3

    	 

    

 

“Change
of Control Transaction”: shall have the meaning ascribed to this term in paragraph (a) of Article 19.

 

“Combination”
shall mean a Co-administration of Product together with any other product.

 

“Compound”:
shall mean RP5264 as described in Annexure I or one of the * Backup Compounds.

 

“Commercialization”,
with a correlative meaning for “Commercialize”: means all activities undertaken before and after obtaining
Regulatory Approval relating specifically to the pre-marketing, launch, promotion, marketing, sale, and distribution of a pharmaceutical
product, including: (a) strategic marketing, sales force detailing, advertising, medical education and liaison, and market and
product support; and (b) any Phase IV Clinical Trials, and (c) all customer support and Product distribution, invoicing and sales
activities.

 

“Confidential
Information”: means, with respect to a Party, all confidential Information of such Party that is disclosed to the other
Party under this Agreement, which may include specifications, know-how, trade secrets, legal information, technical information,
drawings, models, business information, inventions, discoveries, methods, procedures, formulae, protocols, techniques, data, and
unpublished patent applications, in each case whether disclosed in oral, written, graphic, or electronic form.  All Confidential
Information disclosed by either Party pursuant to the Mutual Confidential Disclosure Agreement between the Parties dated April
27, 2012 shall be deemed to be such Party’s Confidential Information disclosed hereunder.

 

“Control”
shall mean,with respect to any material, Information, or intellectual property right, that a Party owns or has a license to
such material, Information, or intellectual property right and has the ability to grant to the other Party access, a license,
or a sublicense (as applicable) to such material, Information, or intellectual property right on the terms and conditions set
forth herein without violating the terms of any agreement or other arrangement with any Third Party existing at the time such
Party would be first required hereunder to grant to the other Party such access, license, or sublicense.

 

“IND/CTA”
shall mean(a) an Investigational New Drug application as defined in the FD&C Act and
applicable regulations promulgated thereunder by the FDA or any successor application or procedure required to initiate clinical
testing of a Product in humans in the Territory; and (b) all supplements and amendments to the foregoing. 

 

“Rhizen
Intellectual Property Rights”: shall mean all Rhizen Patents and Rhizen Know-How.

 

“Rhizen
Know-How”: shall mean (i) all Know-How that is Controlled by Rhizen
or its Affiliates on the Effective Date and during the Term, and (ii) Rhizen’s interest in any Joint Know-How, in each case
that is necessary or useful for the Development, manufacture or Commercialization of the Product. For clarity, Rhizen Know-How
excludes the Rhizen Patents. 

 

 

*
Confidential material redacted and filed separately
with the Commission.

 

    	4

    	 

    

 

“Rhizen
Patent(s)”: shall mean any Patent, including Rhizen’s interest in any Joint Patent, that (a) is Controlled by
Rhizen or its Affiliates on the Effective Date and during the Term, and (b) claims the Product or its manufacture or its use,
or any other invention that is otherwise necessary or useful for the Development, manufacture, use or Commercialization of the
Product in the Field of the Use, including the patents listed in Annexure IIA, which shall be from time to time amended and updated
during the Term to incorporate the then-current Rhizen Patents.

 

“Data”:
shall mean any and all scientific and research data, technical data, test and development data, pre-clinical and clinical
data (including pharmacological, biological, chemical, biochemical, toxicological, pre-clinical and clinical test data, analytical
and quality control data, stability data, results of studies and patient lists), formulations, processes, protocols, regulatory
files and the like which are developed by either Party in connection with the Compound or the Product.

 

“Joint
Know-How”: shall mean all Know-How developed or acquired by either Party in performing its obligations pursuant to the
JV Agreement that is necessary or useful for the Development, manufacture or Commercialization of the Product.

 

“Know-How”:
shall mean any and all technical information, test and development data and results, formulations, processes, ideas, protocols,
regulatory files, preclinical and clinical data (including, without limitation, Data) and the like relating to the use, manufacture,
Development, or Commercialization of the Compound or the Product.

 

“TGTX
Intellectual Property Rights”: shall mean all TGTX Patents and TGTX Know-How.

 

“TGTX
Know-How”: shall mean (i) all Know-How that is Controlled by TGTX or its
Affiliates on the Effective Date and during the Term, and (ii) TGTX’s interest in the Joint Know-How, in each case that
is necessary or useful for the Development, manufacture or Commercialization of the Product. For clarity, TGTX Know-How excludes
TGTX Patents.

 

“TGTX
Patent(s)”: shall mean any Patent, including TGTX’s interest in any Joint Patent, that (a) is Controlled by TGTX
or its Affiliates on the Effective Date and during the Term, and (b) claims the Product or its manufacture or its use, or any
other invention that is otherwise necessary or useful for the Development, manufacture, use or Commercialization of the Product
in the Field of the Use, including the patents listed in Annexure IIB, which shall be from time to time amended and updated during
the Term to incorporate the then-current TGTX Patents.

 

“Develop
or Development”: shall mean all activities relating to preparing and conducting preclinical testing, toxicology testing,
human clinical studies, regulatory affairs for obtaining the Regulatory Approvals, formulation development, process development
for manufacture and associated validation, quality assurance and quality control activities (including qualification lots). Development
shall exclude all Phase IV Clinical Trials.

 

“Development
Plan”: shall mean plans for development of the Product as outlined in Annexure III,
which shall be provided by TGTX and updated and amended pursuant to Section 3.

 

    	5

    	 

    

 

“Diligent
Efforts”: means, with respect to a Party’s obligation under this Agreement to Develop or Commercialize a Product,
the level of efforts and resources required to carry out such obligation in a sustained manner consistent with the efforts and
resources a similarly situated biopharmaceutical company devotes to a product of similar market potential, profit potential or
strategic value within its portfolio, based on conditions then prevailing i.e. it shall mean the efforts required in order to
carry out a task or objective in a diligent and sustained manner without undue interruption, pause or delay, which level is at
least commensurate with the level of efforts that a pharmaceutical company would devote to a product of similar potential and
having similar commercial and scientific advantages and disadvantages as compared to the Product hereunder. Diligent Efforts requires
(without limitation) that the Party exerting such efforts (i) promptly assign responsibility for its obligations to specific employee(s)
or contractor(s) who are held accountable for progress and monitor such progress, on an ongoing basis, (ii) set and continue to
seek to achieve specific and meaningful objectives for carrying out such obligations, and (iii) consistently make and implement
decisions and allocate resources designed to advance progress with respect to such objectives, in each case in a diligent manner.

 

“Major
Market(s)”: shall mean any of the following countries or groups of countries: (i) the United States of America; (ii)
Canada; (iii) France, Germany, Italy, Spain, and the United Kingdom (each, a “Major European Market”);
(iv) Japan; and (v) Russia, Brazil or China (each, a “Major BRIC Market”).

 

“Diligence
Failure”: shall mean TGTX does not correct a failure to use Diligent Efforts within the applicable period specified
in, or determined in accordance with Section 3.2.5(b).

 

“EMEA”:
shall mean the European Medicines Agency or any successor agency thereto.

 

“FDA”:
shall mean the United States Food and Drug Administration, or a successor federal agency thereto.

 

“Field”
means the prevention, treatment or amelioration of any disease or condition in humans. 

 

“Field
of Use”: shall mean the use of Products in the Field as defined herein.

 

“First
Commercial Sale”: shall mean the first commercial sale by TGTX, its Affiliates and/or Sublicensees to a Third Party
of a Product for value in any country in the Territory following receipt of approval to market such Product from the relevant
Regulatory Authority in the applicable country.

 

“Finished
Product” shall mean a Product that has been filled into vials, syringes or capsules or manufactured into other pharmaceutical
presentations for administration, such as tablets or pills; finished and labeled for use in clinical trials or for commercial
purposes in accordance with the applicable specifications and legal requirements.

 

“Generic
Product” means a drug product that (i) contains the same active ingredient as the Product where the Product is the reference-listed
drug, and (ii) is approved by a Governmental Authority pursuant to an Abbreviated New Drug Application, an application under 21
U.S.C. §355(b)(2), or similar application.

 

“Indication”:
means any indication for which (a) a Product is developed pursuant to an IND or CTA (or if no such filing is required, pursuant
to the applicable clinical trial protocol), (b) an NDA for a Product is submitted, or (c) an NDA for a Product is approved by
a Regulatory Authority.

 

    	6

    	 

    

 

“IND”:
shall mean (a) an Investigational New Drug application as defined in the FD&C Act and applicable regulations promulgated
thereunder by the FDA or any successor application or procedure required to initiate clinical testing of a Product in humans in
the Territory; and (b) all supplements and amendments to the foregoing.

 

“Information”
means any data, results, technology, business information, and information of any type whatsoever, in any tangible or intangible
form, including, without limitation, know-how, trade secrets, practices, techniques, methods, processes, inventions, developments,
specifications, formulations, formulae, materials or compositions of matter of any type or kind (patentable or otherwise), software,
algorithms, marketing reports, expertise, technology, test data (including pharmacological, biological, chemical, biochemical,
toxicological, preclinical and clinical test data), analytical and quality control data, stability data, other study data and
procedures. 

 

“Sole
Inventions”: shall have the meaning ascribed to this term in Section 7.1.

 

“Joint
Inventions”: shall have the meaning ascribed to this term in Section 7.1.

 

“Joint
Patents”: shall mean any and all patents and patent applications claiming any Joint Invention, together with any and
all patents issued on any such applications as well as any divisional, continuation, continuation-in-part, substitution applications,
re-issue, re-examination, renewal and extended patents (including supplementary protection certificates (SPC)) of any of the foregoing.

 

“JSC”:
shall mean the joint scientific committee created by the Parties according to Section 4.1

 

“Launch”:
shall mean the First Commercial Sale in a country.

 

“Milestone(s)”:
shall have the meaning ascribed to this term in Section 6.3.

 

“Milestone
Payment”: means any of the Primary Indication Milestone Payments, the Secondary Indication Milestone Payments, and the
Non-Oncology Indication Milestone Payments.

 

“NDA”:
shall mean a “New Drug Application” (as more fully defined in 21 C.F.R. 314.5 et seq.) filed with the FDA
or the equivalent application filed with any other Regulatory Authority to obtain marketing approval for a Product in a country
or jurisdiction in the Territory.

 

“Net
Sales”: shall mean, with respect to a particular time period, the total amounts received or invoiced by TGTX, its Affiliates,
and sublicensees (subject to the provisions set forth in Section 6) for sales of Product made during such time period to unaffiliated
Third Parties, less the following deductions to the extent actually allowed or incurred with respect to such sales:

 

		(a)	discounts,
                                         including cash, trade, and quantity discounts, retroactive price reductions, charge-back
                                         payments, and rebates actually granted or administrative fees actually paid to trade
                                         customers, patients (including those in the form of a coupon or voucher), managed health
                                         care organizations, pharmaceutical benefit managers, group purchasing organizations,
                                         federal, state, or local government and the agencies, purchasers and reimbursers of managed
                                         health organizations, pharmaceutical benefit managers, group purchasing organizations,
                                         or federal, state or local government;

 

    	7

    	 

    

 

		(b)	credits
                                         or allowances actually granted upon prompt payment, or losses, actually incurred as a
                                         result of damaged goods, rejections or returns of such Product, including in connection
                                         with recalls, and all other reasonable and customary allowances and adjustments actually
                                         credited to customers;

 

		(c)	packaging,
                                         freight, postage, shipping, transportation, warehousing, handling and insurance charges,
                                         credit card processing fees and any customary payments with respect to the Products actually
                                         made to wholesalers or other distributors, in each case actually allowed or paid for
                                         distribution and delivery of Product, to the extent billed or recognized; and

 

		(d)	taxes,
                                         including sales taxes, excise taxes, value-added taxes, and other taxes (other than income
                                         taxes), duties, tariffs or other governmental charges levied on the sale of such Product,
                                         including, without limitation, value-added and sales taxes.

 

Notwithstanding
the foregoing, amounts received or invoiced by TGTX, its Affiliates and sublicencees for the sale of Product among TGTX, its Affiliates
and sublicencees shall not be included in the computation of Net Sales hereunder. In any event, any amounts received or invoiced
by TGTX and its Affiliates or sublicensees shall be accounted for only once. Subject to the provisions of Section 6, Sublicensee
Royalties and Sublicensing Payments shall not be included in Net Sales. Net Sales shall be accounted for in accordance
with U.S. Generally Accepted Accounting Principles (“GAAP”) consistently applied. Net Sales shall exclude any samples
of Product transferred or disposed of at no cost for promotional or educational purposes, and the cost for such samples transferred
or disposed of shall be deemed to be included in the Commercial Expenses.

 

For the purposes
of determining royalty rates and the royalties payable on Combination, Net Sales of Product shall be calculated by multiplying
the Net Sales of the Combination by the fraction A/A+B, where A is the average selling price, during the royalty paying period
in question, of the Product sold separately in the country in which the sale of the Combination is made, and B is the average
selling price, during the royalty period in question, of the other active ingredient(s) or component(s) sold separately.  In
the event that such average selling price cannot be determined for both Product and all other active ingredient(s) and component(s)
included in the Combination Product, Net Sales for purposes of determining payments under this Agreement shall be calculated by
multiplying the Net Sales of the Combination by the fraction C/(C+D) where C is the standard fully-absorbed cost of the portion
of the combination, and D is the standard fully-absorbed cost of the other active ingredient(s) or component(s) included in the
Combination, as determined by TGTX using its standard accounting procedures consistently applied. In the event that the standard
fully-absorbed cost of the Product and/or the other active ingredient(s) or component(s) included in such Combination cannot be
determined, for the purposes of determining royalties payable hereunder, the Parties shall negotiate in good faith to determine
an appropriate commercial value for all the components in the Combination and calculate Net Sales of such Combination accordingly.

 

    	8

    	 

    

 

Further, the
Parties agree to negotiate in good faith for an equitable determination of the Net Sales of the Product in the event TGTX and
its Affiliates sells the Product in such a manner that gross sales of the Product are not readily identifiable. In addition, for
purposes of this Agreement, “sale” shall mean any transfer or other distribution or disposition, but shall not include
transfers or other distributions or dispositions of Product at no charge for academic research, preclinical, clinical, or regulatory
purposes (including the use of a Product in Clinical Trials) or in connection with patient assistance programs or other charitable
purposes or to physicians or hospitals for promotional purposes (including free samples to a level and in an amount which is customary
in the industry and/or which is reasonably proportional to the market for such Product).

 

“Non-Oncology
Indication”: shall mean any Indication other than an oncology Indication.

 

“Party”:
shall mean either TGTX or Rhizen, as the context requires, or both TGTX and Rhizen when used in the plural form

 

“Patent(s)”:
shall mean (a) pending patent applications, including provisional patents, issued patents, utility models and designs;
and (b) extensions, reissues, substitutions, confirmations, registrations, validations, re-examinations, additions, continuations,
continued prosecution applications, requests for continued examination, continuations-in-part, or divisions of or to any patents,
patent applications, utility models or designs.

 

“Phase
I Clinical Trial”: means a small scale trial of a pharmaceutical product on subjects that generally provides for the
first introduction into humans of such product with the primary purpose of determining safety, metabolism and pharmacokinetic
properties, clinical pharmacology and any other properties of such product as per the study protocol design, as required by 21
C.F.R. 312(a) or a similar study in other countries.

 

“Phase
II Clinical Trial”: means a small scale clinical trial of a pharmaceutical product on patients, including possibly pharmacokinetic
studies, the principal purposes of which are to make a preliminary determination that such product is safe for its intended use
and to obtain sufficient information about such product’s efficacy to permit the design of further clinical trials, as required
by 21 C.F.R. 312(b) or a similar study in other countries.

 

“Phase
III Clinical Trial”: means one or more clinical trials on sufficient numbers of patients, which trial(s) are designed
to (a) establish that a drug is safe and efficacious for its intended use; (b) define warnings, precautions and adverse
reactions that are associated with the drug in the dosage range to be prescribed; and (c) support Regulatory Approval of
such drug, as required by 21 C.F.R. 312(c) or a similar study in other countries.

 

“Primary
Indications”: means * and *.

 

“Product(s)”:
shall mean a pharmaceutical preparation in any formulation that contains the Compound as an active ingredient.

 

“New
Product”: shall mean a pharmaceutical preparation containing Compound which differs from a previously approved product
by at least one active pharmaceutical ingredient. 

 

“Governmental
Authority”: means any multi-national, federal, state, local, municipal or other government authority of any nature (including
any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal).

 

 

*
Confidential material redacted and filed separately with the Commission.

 

    	9

    	 

    

 

“Good
Clinical Practices” or “GCP” means the then-current good clinical practice standards, practices and
procedures promulgated or endorsed by the FDA as set forth in the guidelines entitled “Guidance for Industry E6 Good Clinical
Practice: Consolidated Guidance,” including related regulatory requirements imposed by the FDA, and comparable regulatory
standards, practices and procedures in jurisdictions outside the U.S., in each case as they may be updated from time to time.

 

“Good
Laboratory Practices” or “GLP” means the then-current good laboratory practice standards promulgated
or endorsed by the FDA as defined in 21 C.F.R. Part 58, and comparable regulatory standards in jurisdictions outside the
U.S., in each case as they may be updated from time to time. 

 

“Good
Manufacturing Practices” or “GMP” means the then-current good manufacturing practices required by
the FDA, as set forth in the FD&C Act and the regulations promulgated thereunder, for the manufacture and testing of pharmaceutical
materials, and comparable Laws applicable to the manufacture and testing of pharmaceutical materials in jurisdictions outside
the U.S., including without limitation 21 CFR 211 (Current Good Manufacturing Practice for Finished Pharmaceuticals) and the guideline
promulgated by the International Conference on Harmonization designated ICH Q7A, entitled “Q7A Good Manufacturing Practice
Guidance for Active Pharmaceutical Ingredients” and associated guidelines and regulations, in each case as they may be updated
from time to time. 

 

“Regulatory
Approvals” means all approvals (including without limitation supplements, amendments, and pricing approvals), licenses,
registrations or authorizations of any national, supra-national, regional, state or local regulatory agency, department, bureau,
commission, council or other governmental entity, necessary for the manufacture, storage, import, transport, distribution, marketing,
use or sale of a pharmaceutical product in a given regulatory jurisdiction.

 

“Regulatory
Authority”: means, in a particular country or jurisdiction, any applicable Governmental Authority involved in granting
Regulatory Approval in such country or jurisdiction, including without limitation, in the U.S., the FDA and any other applicable
Governmental Authority in the U.S. having jurisdiction over the Product, and, in the European Union, the EMEA and any other applicable
Governmental Authority having jurisdiction over the Product..

 

“Royalties”:
shall mean the royalties to be paid by TGTX to Rhizen (a) on the basis of Net Sales pursuant to Section 6.3.3 hereof, or (b)
on the basis of Sublicensee Royalties, pursuant to Section 6.4.2 hereof, as applicable.

 

“Royalty
Term”: shall mean, on a country-by-country basis, the period beginning upon the First Commercial Sale of a Product or
New Product in a country and ending on the later of (i) on the expiration of the last to expire issued Valid
Claim within the Licensed Patents covering the sale of the Product or
New Product in such country, or (ii) expiry of any other exclusivity right with respect to the Product or New Product in a country,
including patent term extensions, marketing exclusivity or any other non-patent exclusivity.

 

“Secondary
Indication”: means any oncology indication other than a Primary Indication.

 

“Subcontractor”:
means a Third Party service provider engaged by TGTX to perform contract services on behalf of TGTX or its Affiliates, where
TGTX retains a meaningful participatory role in the overall development and commercialization of the Product (e.g., contract
research or development organizations, clinical sites performing clinical trials, universities and scientific institutes, distributors
in certain countries in the Territory, or contract manufacturing organizations).

 

    	10

    	 

    

 

“Sublicensee(s)”:
shall mean any Third Party to whom TGTX, or any of its Affiliates, has sublicensed any of TGTX’s rights under the license
granted to TGTX pursuant to Section 2.1.

 

“Sublicensee
Royalties”: shall mean all royalties paid by any Sublicensee to TGTX or any of its Affiliates with respect to sales
of Products by such Sublicensee or its further sublicensees.

 

“Sublicensing
Payments”: shall mean consideration in any form received by TGTX or any of its Affiliates in connection with a grant
to any Third Party(ies) of a sublicense or other right, license, privilege or immunity to develop, have developed, make, have
made, use, sell, have sold, distribute, import or export Products, but excluding Sublicensee Royalties. Sublicensing Payments
shall include, without limitation:

 

(i)
any upfront or license signing fee;

 

(ii)
any license maintenance fee;

 

(iii)
any milestone payments (including, without limitation development, regulatory and sales-based milestone payments);

 

(iv)
the portion of any minimum royalty payment received by TGTX or any of its Affiliates in excess of Sublicensee Royalties received;

 

(v)
if a Sublicensee issues equity or debt securities to TGTX or its Affiliate in connection with a sublicense grant, the fair market
value of such securities issued to TGTX or its Affiliate (such fair market value to be determined by agreement of TGTX and Rhizen
or by an independent appraiser mutually agreeable to TGTX and Rhizen), net of any cash consideration paid by TGTX or its Affiliate
for such securities;

 

(vi)
any distribution or joint marketing fee;

 

(vii)
research and development funding in excess of TGTX’s or its Affiliates’ actual cost of performing such research and
development (calculated on a fully-burdened basis in accordance with TGTX’s or its Affiliate’s project- or activity-based
accounting practices, as applied consistently throughout its accounting system); and

 

(viii)
if TGTX or its Affiliate sells equity or debt securities to a Sublicensee in connection with a sublicense grant, any consideration
received by TGTX or its Affiliate for such securities to the extent such consideration exceeds the fair market value of such securities
(such fair market value to be determined by agreement of TGTX and Rhizen or by an independent appraiser mutually agreeable to
TGTX and Rhizen). 

 

“Technology
Transfer Plan”: shall have the meaning ascribed to this term in Section 3.1.1.

 

“Territory”:
shall mean the entire world excluding India.

 

“TGTX
Exercise Fee”: shall have the meaning ascribed to this term in Section 6.2. 

 

“Third
Party”: shall mean any entity other than TGTX or Rhizen or an Affiliate of TGTX or Rhizen.

 

    	11

    	 

    

 

“Valid
Claim” shall mean (a) any claim of an issued unexpired patent that (i) has not been permanently revoked, held
invalid, or declared unpatentable or unenforceable in a decision of a court or other body of competent jurisdiction that is unappealable
or unappealed within the time allowed for appeal, and (ii) is not lost through an interference proceeding that is unappealable
or unappealed within the time allowed for appeal; or (b) provided there is no Generic Product available in the market, a claim
of a pending Patent application, which claim has not been abandoned or finally disallowed without the possibility of appeal.

 

2 LICENSE 

 

2.1 Subject
to the terms and conditions of this Agreement, Rhizen grants to TGTX an exclusive license under the Rhizen Intellectual Property
Rights, to develop, have developed, use, have used, sell, have sold, offer for sale, register, have registered, Commercialize,
and have Commercialized and import the Product for any Indication in the Field of Use in the Territory. For avoidance of doubt,
Rhizen does not grant to TGTX any right or license with respect to any API other than the Compound, as defined herein above. Subject
to the terms and conditions of this Agreement, Rhizen retains the exclusive right to manufacture the Product, including the Bulk
API and Finished Product in the Territory.

 

2.2 The license
granted to TGTX by Rhizen under Section 2.1 includes the right for TGTX to grant sublicenses to its Affiliates and to Third Parties
for the development, manufacture, sale and/or commercialization of the Compound and the Product. All sublicenses granted by TGTX
shall be subject to the terms and conditions of this Agreement and TGTX shall enter into a written sublicense agreement with each
Sublicensee which will contain terms and conditions fully consistent with the terms and conditions contained in this Agreement.
TGTX shall use Diligent Efforts to include in any Commercial Sublicense Agreement express permission to assign all of the rights
and obligations under such agreement to Rhizen without consent from the Sublicensee. TGTX shall provide to Rhizen a draft copy
of each Commercial Sublicense Agreement (as defined below) intended to be entered into by TGTX or any of its Affiliates and any
immediate Sublicensee, in each case, for a period of 30 (days) days before execution of such Commercial Sublicense Agreement to
allow Rhizen to ascertain if the terms and conditions set forth therein are fully consistent with the terms and conditions contained
in this Agreement, provided that TGTX may redact in its entirety from such draft
any sensitive, confidential or proprietary information that is not necessary
to ascertain TGTX’s, its Affiliate’s or a Sublicensee’s compliance with the terms and conditions of this Agreement
(including, without limitation, TGTX’s payment and reporting obligations hereunder). TGTX shall provide to Rhizen a true
and complete copy of each Commercial Sublicense Agreement entered into by TGTX or any of its Affiliates and any Sublicensee, and
of each amendment to any such Commercial Sublicense Agreement, in each case, within thirty (30) days after execution of such Commercial
Sublicense Agreement or amendment. For the purpose of this Section 2.2, the term “Commercial Sublicense Agreement”
shall mean any agreement executed by TGTX or any of its Affiliates under which any of TGTX’s rights under the license
granted to TGTX pursuant to Section 2.1 are sublicensed; provided, however, that the term Commercial Sublicense Agreement
shall exclude any agreement between TGTX or its Affiliate and a Subcontractor. In addition, TGTX shall notify Rhizen in writing
of the termination of any Commercial Sublicense Agreement within thirty (30) days after such termination. If TGTX determines that
there is a reasonable likelihood of its execution of a Commercial Sublicense Agreement or an amendment to, or termination of,
an existing Commercial Sublicense Agreement, TGTX shall use reasonable efforts to provide notice thereof to Rhizen, which notice
shall be provided solely for Rhizen’ information and planning purposes. No sublicense hereunder shall limit or affect the
obligations of TGTX under this Agreement, and TGTX shall remain fully responsible for each Affiliate’s or Sublicensee’s
compliance with the applicable terms and conditions of this Agreement. TGTX agrees to take Diligent Efforts to enforce the terms
of each Commercial Sublicense Agreement against the relevant Sublicensee in the event of a material breach thereof.

 

    	12

    	 

    

 

2.3 TGTX may
subcontract certain activities to Subcontractors who will conduct such activities, or a portion thereof, on behalf of TGTX. TGTX’s
execution of a subcontracting agreement with any Subcontractor shall not relieve TGTX of any of its obligations under this Agreement.
TGTX shall remain directly liable to Rhizen for any performance or non-performance of a Subcontractor that would be a breach of
this Agreement if performed or omitted by TGTX, and TGTX shall be deemed to be in breach of this Agreement as a result of such
performance or non-performance of such Subcontractor. TGTX shall use Diligent Efforts to include in any agreement with a Subcontractor
express permission to assign all of the rights and obligations under such agreement to Rhizen without consent from the Subcontractor.
TGTX agrees to take Diligent Efforts to enforce the terms of each subcontractor agreement, the breach of which would constitute
a breach of this Agreement if performed or omitted by TGTX, against the relevant Subcontractor in the event of a material breach
thereof.

 

2.4 Except
as expressly provided in this Agreement, no license or other right is or shall be created or granted hereunder by implication,
estoppel or otherwise.

 

3 DEVELOPMENT
PLAN 

 

3.1. Obligations
of Rhizen

 

3.1.1 As soon
as possible after the Effective Date, Rhizen shall transfer to TGTX, all Rhizen Intellectual
Property (excluding Rhizen Patents) that is necessary for TGTX to continue the development of the Compound and the Products
in accordance with the Development Plan and transfer the information and materials set forth in the technology transfer plan attached
hereto as Annexure IV (the “Technology Transfer Plan”) on the timeline set forth in the Technology Transfer
Plan. Rhizen shall supply TGTX at TGTX’s cost, as indicated in this Section 3.1.1, as soon as possible, but in any event
within thirty (30) days, with the amount of API or Finished Product (qty) for use in clinical studies that is requested by TGTX,
unless the costs associated with the manufacture of such products were previously shared by both Parties pursuant to the JV Agreement,
in which case TGTX shall reimburse Rhizen that portion of the cost paid by Rhizen pursuant to the JV Agreement. TGTX shall
make payment on Rhizen’ invoices under this Section 3.1.1 within Thirty (30) days of invoice.

 

3.1.2 At no
cost to TGTX, Rhizen shall provide a reasonable amount of technical, scientific and intellectual property support to the Development
Plan, as requested by TGTX, during the first three (3) month period beginning on the Effective Date unless the costs associated
with such support has been already shared by both Parties pursuant to the JV Agreement.

 

3.1.3 Rhizen
agrees that it will not develop, have developed, Commercialize or have Commercialized the Compound for non-human uses, including
without limitation, veterinary uses, while the Compound is under Active Clinical Development or, following Regulatory Approval
of the Compound in any Major Market, while the Compound is subject to Active Commercialization; provided, however, Rhizen shall
be free to develop, have developed, Commercialize, or have Commercialized, the Compound for non-human use, including without limitation
veterinary use, if at the end of the fifth year following the first Regulatory Approval of a Product in any Major Market TGTX
has not paid to Rhizen in the aggregate at least * Dollars ($ * ) in Royalties
hereunder. In addition, and notwithstanding the foregoing, following the completion of Active Clinical Development, Rhizen may
develop, have developed, Commercialize, or have Commercialized, the Compound for a non-human use, including without limitation
veterinary use, provided that such development or Commercialization is in the form of a co-formulation of the Compound with any
other active additional ingredient.

 

 

 

*
Confidential material redacted and filed separately with the Commission.

 

    	13

    	 

    

 

3.2 Obligations
of TGTX

 

3.2.1 TGTX
shall undertake Diligent Efforts to Develop, register and Commercialize the
Product in the Field of Use in the Major Markets and in such other markets as TGTX deems commercially reasonable. TGTX shall use
Diligent Efforts to maximize Net Sales and shall not take any action with the intent of reducing or avoiding the Milestone Payments
or any royalties hereunder. From and after the Effective Date, TGTX shall be solely responsible for all the costs relating to
the Development, registration and Commercialization of the Product in the Field of Use. TGTX shall solely assume the managing
and the financing of the Development Plan, with the objective of verifying the safety, potency and efficacy of the Product and,
if the results of clinical development are positive, filing applications for NDA approval in an expeditious manner, within the
limits of the demands of the Regulatory Authorities and consistent with Diligent Efforts, as more fully described below in this
Section 3.2. TGTX shall retain final decision making authority on all Development, Commercialization, marketing, manufacturing
and regulatory matters relating to the Product; provided, however, that TGTX shall:
(i) provide Rhizen the opportunity to review and comment on protocols for clinical trials of which TGTX or its Affiliate
will be the sponsor and proposed labelling for the Product in each country of the Territory, in each case, reasonably in advance
of submission by TGTX or any of its Affiliates (but, for the avoidance of doubt, not Sublicensees) to the applicable Regulatory
Authority of any such clinical trial protocol or any regulatory filing regarding Product labelling, and (ii) consider Rhizen’s
comments with respect to such clinical trial protocols and Product labelling in good faith,
provided such comments are provided in an expeditious manner consistent with Diligent Efforts by TGTX.

 

3.2.2 TGTX
shall conduct the activities set forth in the Development Plan in accordance with all applicable Laws and current good manufacturing
practice (cGMP), current good laboratory practice (cGLP) and current good clinical practice (cGCP), where applicable.

 

3.2.3 The Development
Plan will be updated from time to time in accordance herewith and such updates shall be attached hereto as Annexure III.
The Development Plan indicates in reasonable details TGTX’s plans for the Development of Product in the Field of
Use, including regulatory and registration strategy consistent with Diligent Efforts. Without limiting the generality of any of
the foregoing obligations in this Section 3.2.3, TGTX shall use Diligent Efforts to Develop the Product. TGTX may reasonably revise
and amend the Development Plan from time to time upon as much advance notice to Rhizen as is practicable under the circumstances,
so long as such amended Development Plan meets the criteria described above.

 

    	14

    	 

    

 

3.2.4 If at
any time TGTX definitively and formally suspends its research or development efforts for the Product, or definitively and formally
makes an internal determination to suspend research and development of the Product, for a period exceeding sixty (60) days, TGTX
shall notify Rhizen giving reasons and a statement of its intended actions.

 

3.2.5 TGTX
shall be obligated to make Diligent Efforts to Develop, itself or through Affiliates, subcontractors and/or Sublicensees, at least
one (1) Compound. If Rhizen considers that TGTX has failed to exercise Diligent Efforts, then Rhizen shall notify TGTX in writing
within sixty (60) days of appearance of such potential failure thereof stating in reasonable detail the particular alleged failure.

 

(a)
If TGTX disagrees with Rhizen’s claim that TGTX has failed to exercise Diligent Efforts, TGTX shall so notify Rhizen in
writing within thirty (30) days after receipt of Rhizen’s notice, in which event the Parties shall promptly refer the matter
to a Third Party expert in drug development, completely unaffiliated and independent of the Parties and jointly selected by the
Parties, to determine whether a failure by TGTX to use Diligent Efforts occurred, or if the related problem was due to some other
cause. Neither Party shall unreasonably withhold or delay its approval of such expert. The Parties shall initially share equally
the fees and costs of such expert, but promptly after such expert makes a determination regarding the matter, the non-prevailing
Party shall reimburse the prevailing Party for the share of such fees and costs borne by the prevailing Party. Should it be determined
by the expert that such failure resulted from TGTX’s failure to use Diligent Efforts to Develop the Product, then the expert
shall determine what corrective action by TGTX would best meet the standard of Diligent Efforts and a timeframe for the completion
of such corrective action by TGTX. The determination of such expert shall be final and binding on the Parties.

 

(b) If TGTX
does not correct such alleged failure either: (i) within ninety (90) days after notice of such alleged failure from Rhizen; or
(ii) if TGTX disputes Rhizen’s allegation of failure to use Diligent Efforts in accordance with the preceding paragraph
(a), within the period specified by the expert; then, in each case, subject to Section
14, Rhizen shall have the right to terminate this Agreement in accordance with Section 12.3.

 

3.2.6 TGTX
shall maintain reasonable records of its
work, including research, development, clinical, manufacturing and commercialization activities with respect to the Product
conducted by TGTX under this Agreement, together with all results, data and developments made or generated in connection with
any of the foregoing. Such records shall fully and properly reflect all work done and results achieved in the performance of this
Agreement in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes.

 

3.2.7 During
the Term, TGTX shall keep Rhizen regularly informed in reasonable detail regarding TGTX’s worldwide Product development.
The detailed minutes of the JSC shall constitute the written progress report summarizing the status of the Product development,
clinical trial progress, regulatory approval and commercialization. In addition, throughout the Term, TGTX shall notify Rhizen
promptly of the occurrence of the following with respect to a Product: (i) initiation of any Phase II Clinical Trial in a Major
Market; (ii) initiation of any Phase III Clinical Trial in a Major Market; (iii) NDA filing in any Major Market; (iv) NDA approval
in any Major Market; and (v) First Commercial Sale in any Major Market. TGTX shall also respond to reasonable (i.e., not
unduly frequent or burdensome) informal requests from Rhizen for additional information regarding the development of the Product
from time to time.

 

    	15

    	 

    

 

3.2.8 Rhizen
agrees that the results of the Development Plan cannot be accurately predicted, that TGTX’s obligation with respect to the
Development Plan is not an obligation to obtain a particular result and that TGTX does not warrant or guarantee that the Development
Plan will yield any useful or anticipated results.

 

3.2.9 Before
the second anniversary of the Effective Date, TGTX shall select up to * Backup
Compounds for Development and Commercialization hereunder from the then current list of possible Backup Compounds in Annexure
VI. After the second anniversary of the Effective Date, TGTX shall not be able select any other Backup Compounds.

 

4 JOINT SCIENTIFIC
COMMITTEE 

 

4.1 The JSC
shall be comprised of a minimum of Four (4) committee members, which shall consist of two (2) representatives nominated by each
Party. Representatives will include persons having knowledge in the areas of responsibility of the JSC. The Parties may mutually
agree to change the total number of representatives on the JSC, provided that the Parties always have an equal number of representatives.
Each Party may replace any of its JSC representatives at any time upon written notice to the other Party. The JSC may invite non-members
to participate in the discussions and meetings of the JSC, including experts bound by appropriate confidentiality obligations.
The JSC shall continue to exist and meet during the Term or until the Parties mutually agree that it should disband. Each Party
shall be responsible for all travel and related costs for such Party’s representatives and guests to attend meetings of,
and otherwise participate on, the JSC.

 

4.2
The JSC shall meet at least thrice (3) during the first year of the Term and twice (2) thereafter at times established by the
Parties. Each Party shall also have the right to request additional meetings of the JSC for good reason. Meetings will be held
in-person, by videoconference or by teleconference. If a meeting is held in-person,
it shall be either (i) in a US city which is hosting a
medical conference that the JSC members are otherwise attending or (ii) at a
mutually agreeable city that is located approximately equidistant from each Parties principal place of business. In the event
that a JSC member of a Party cannot attend a meeting, such Party shall have the right to nominate another representative of that
Party to attend the meeting. 

 

4.3 Throughout
the Term, the JSC shall function to facilitate the collaboration and relationship of the Parties under this Agreement, and facilitate
the communication and exchange of information related to research and development of Products. In addition, for so long as the
JSC is in existence, Rhizen shall provide reasonable technical and scientific support to the Development Plan through its participation
on the JSC.

 

4.4 The JSC
does not have any authority beyond the matters set forth above in this Article 4, and cannot in any way amend or modify the terms
or provisions of this Agreement, either directly or indirectly. Subject to the terms and conditions set forth in this Agreement,
TGTX shall have the sole and final right to take decisions with regard to the development of the Product, including,
without limitation, “Go” and “No Go” decisions, which decisions shall be made in good faith and
consistent with the objectives and intentions of this Agreement. TGTX shall consider
the proceedings of the JSC, and the information presented therein, in good faith, provided, however, that TGTX retains the sole
discretion to make decisions regarding the Product and all matters relevant to this Agreement and is in no way bound by actions
or determinations of the JSC.

 

 

*
Confidential material redacted and filed separately with the Commission.

 

    	16

    	 

    

 

4.5 TGTX shall
circulate a draft of the minutes of each meeting to all members of the JSC for comments within fifteen (15) days after such meeting.
Such minutes shall summarize in reasonable detail the discussions
at the meeting, a list of any actions or determinations by the JSC at such meeting, and a description of any issues within the
JSC that were not resolved at such meeting. Rhizen shall promptly provide to TGTX any comments Rhizen may have regarding the draft
minutes, and the Parties shall discuss the same in good faith and use all reasonable efforts to finalize the minutes no later
than thirty (30) days after such JSC meeting. All final JSC minutes must be signed by both Parties.
In the event the Parties do not agree, the TGTX version of the minutes shall be considered final.

 

5. GLOBAL RIGHT
FOR MANUFACTURE, RELEASE AND SUPPLY OF THE PRODUCT 

 

5.1 Global
Material & Supply Rights. Rhizen shall retain exclusive rights for manufacturing and supply of API and formulations
for global development and commercialization; provided however, that Rhizen’s price is cost competitive (as described in
5.2(b)) and prior to the First Commercial Sale, the Parties shall timely negotiate in good faith and enter into a manufacturing
and supply agreement. Such Commercial Supply Agreement shall contain customary terms governing such manufacturing and supply relationships,
and shall provide as follows:

 

(a)
Rhizen shall establish, by itself or through agreements with Third Parties, an appropriate manufacturing facility or contract
manufacturer for the commercial Finished Product manufacture in a timely manner to ensure that Rhizen meets its obligation to
supply quantities of Finished Product ordered by TGTX under the Commercial Supply Agreement. As further detailed in the Commercial
Supply Agreement, upon the material and uncured breach by Rhizen of its defined supply obligations as set forth in the Commercial
Supply Agreement, TGTX shall have the right to obtain transfer and Rhizen shall have the obligation to give transfer (the distribution
of costs for such transfer to be determined by the parties) unless otherwise determined by JSC to TGTX, without undue delay, of
any and all manufacturing technology necessary to enable it to manufacture or have manufactured Finished Product to meet its requirements
under this Agreement. As further detailed in the Commercial Supply Agreement, if such transfer occurs, Rhizen would grant TGTX
any additional licenses necessary to enable TGTX to exercise the foregoing manufacturing right but requiring TGTX to pay any additional
consideration for such licenses. 

 

(b)
Rhizen shall be responsible for the Finished Manufacture, testing (including stability testing)
and final release of the Finished Product for Commercialization in the Territory. 

 

(c)
The Parties each covenant and agree that all supply agreements executed regarding the provision of any product or material pursuant
to this Agreement, shall contain customary representations and warranties regarding the manufacture of such products and materials,
including, but not limited to, that all materials shall be manufactured, handled and stored: (i) in accordance with the agreed
upon specification and (ii) in compliance with applicable Laws and regulations, including, without limitation, the GMP requirements.

 

    	17

    	 

    

 

5.2         
Manufacturer Source.

 

		(a)	The
                                         Parties shall establish an appropriate facility or contract manufacturing organization
                                         for handling Finished Manufacture as follows: Rhizen shall be responsible for
                                         screening potential manufacturers, negotiating the applicable supply agreement, and effecting
                                         the technology transfer as necessary to establish and qualify Bulk API and Finished Product
                                         manufacturers, whether those are Rhizen, its Affiliates, or Third Parties; provided,
                                         that, TGTX shall have the right to provide reasonable input regarding the terms of such
                                         agreements (as well as any amendments thereof), review and comment on agreement drafts
                                         and forms, consult with Rhizen regarding the negotiation of such agreements between Rhizen
                                         and Third Party contract manufacturers, and conduct a general GMP/regulatory inspection
                                         of the proposed manufacturing facilities as the Parties may agree, it being understood
                                         that TGTX shall retain the final authority over the terms and conditions of any such
                                         agreements with such Third Party contractors..

 

		(b)	Notwithstanding
                                         5.2(a), Rhizen shall be responsible for using Diligent Efforts to minimize the manufacturing
                                         cost of the Finished Product. In order to ensure a competitive rate of manufacturing
                                         cost is obtained, the facility or contract manufacturer used by Rhizen to produce
                                         the Finished Product must provide a total
                                         manufacturing cost within *
                                         % of the cost an alternative contract
                                         manufacturing organization of equal repute and quality,
                                         where the comparative manufacturing cost are measured as an average of such cost over
                                         the immediately preceding Twelve (12) month period.
                                         In the event that Rhizen does not provide manufacturing services at the cost required
                                         in this Section 5.2(b), then TGTX shall have the right to directly procure manufacturing
                                         services in its sole discretion. 

 

6 CONSIDERATION

 

6.1 As consideration
for the exclusive license rights provided in Section 2.1, TGTX shall pay to Rhizen the amounts set forth in this Article 6.

 

6.2 Exercise
Fee

 

Upon the Effective
Date of this Agreement, TGTX shall pay to Rhizen a fully earned, non-refundable, one-time, up-front license fee equal to the sum
of Eight Million Dollars ($8,000,000) (the “Exercise Fee”), which shall be payable fifty percent (50%) in cash
and fifty percent (50%) in shares of TGTX Common Stock (the “Exercise Shares”).

 

Upon signature
of this Agreement, Rhizen shall provide an original invoice for the TGTX Exercise Fee to TGTX, who shall pay the cash portion
of the Exercise Fee within fifteen (15) days of receipt of such invoice.

 

For payments
made in Exercise Shares pursuant to this Section 6.2, such portion of the Exercise Fee shall be made through the issuance of that
number of shares of Common Stock of TGTX as shall equal a fraction where the numerator is FourMillion Dollars ($4,000,000)
and the denominator is the Average Closing Price. For purposes of this Section 6.2, the “Average Closing Price”
means the volume weighted average of the closing prices of TGTX Common Stock on The NASDAQ Global Market (or, if the Common Stock
of TGTX is not listed on the NASDAQ Global Market, the principal exchange or interdealer quotation system on which the TGTX Common
Stock is listed) for the ten (10) trading days prior to the Effective Date; provided, however, that in the event that TGTX effects
a stock split, combination or stock dividend at any time during such 10 trading days or subsequent thereto and prior to the issuance
of the Initial Shares, the number of shares of TGTX Common Stock issuable shall be appropriately adjusted to give effect to such
action. Within five (5) business days of the Effective Date, TGTX shall issue to Rhizen certificates representing the Initial
Shares.

 

 

*
Confidential material redacted and filed separately with the Commission.

 

    	18

    	 

    

 

6.3 Milestones
and Royalties

 

6.3.1 NDA
Filing Payment

 

(a) NDA
filing payment: Whether such event is achieved by TGTX, its Affiliates, its Sublicensees or any Third Party acting on behalf
of TGTX, its Affiliates or its Sublicensees, TGTX shall pay Rhizen a fully earned, non-refundable, one-time, milestone
payment of * Dollars ($ * ) upon the filing an NDA (the “NDA
filing”).”

 

6.3.2 Approval
and Sales Milestone:

 

a.         Sales
Milestones. TGTX shall pay the sales milestone payments set forth below (which, when paid, shall be considered fully earned
and non-refundable) for each Product and for each New Product following approval of such Product or New Product for commercialisation
and achievement of the events set forth in the table below (each, a “Sales Milestone Payment”). The Sales Milestone
Payments shall be paid only once per Product and New Product for each of the events set forth in this Section 6.3.2(a), whether
such milestone event is achieved by TGTX, its Affiliates, its Sublicensees (but only in the event that the sublicense is executed
subsequent to the NDA filing), or any Third Party acting on behalf of TGTX, its Affiliates, or its Sublicensees. No payment shall
be due for any milestone event which is not achieved. For clarity, so long as the Product was approved for commercialization for
a first indication, if the Product is later approved for additional indications, all sales of the Product for any indication will
be counted toward the sales milestone event for such Product.

 

	Sales
    Milestones	$
    * on achieving gross sales of $ *	 	$
    *
	$ *
    on achieving gross sales of $ *	 	$
    *
	$
    * on achieving gross sales of $ *	 	$
    *
	 	Sales
    Milestones Subtotal	 	$
    *

 

b.         Primary
Indication Approval Milestones. TGTX shall pay the milestone payments set forth below (which, when paid, shall be considered
fully earned and non-refundable) for each Product and for each New Product following approval for commercialisation for one of
the Primary Indications and achievement of the events set forth in the table below (each, a “Primary Indication Milestone
Payment”). The Primary Indication Milestone Payments shall be paid only once per Product and once per New Product for
each of the events set forth in this Section 6.3.2(b), whether such milestone event is achieved by TGTX, its Affiliates, its Sublicensees
(but only in the event that the sublicense is executed subsequent to the NDA filing), or any Third Party acting on behalf of TGTX,
its Affiliates, or its Sublicensees. No payment shall be due for any milestone event which is not achieved

 

 

*
Confidential material redacted and filed separately with the Commission.

 

    	19

    	 

    

  

	 	Milestone(s)
    	 	 	 	 
	 	Milestone
    For Each Product  approved for Primary Indication	 	 	 	 
	Approval	$
    * on US Launch	 	 	 	$
    *
	$
    * on EMA Launch	 	 	 	$
    *
	$
    * on Japan Launch	 	 	 	$
    *
	$
    * on each of China, Russia, Brazil Launch	 	 	 	$
    *
	 	Approval
    Subtotal	 	 	 	$
    *
	 	 	 	 	 	 	 

If the milestone
events in this Section 6.3.2(b) are achieved for a Product or a New Product following approval for a Primary Indication, TGTX
shall be required to pay the corresponding approval milestone payments under this Section 6.3.2(b) for such Product or New Product
notwithstanding that an approval milestone was already paid under Section 6.3.2(c) for a Secondary Indication.

 

c.         Secondary
Indication Approval Milestone. TGTX shall pay the milestone payments set forth below (which, when paid, shall be considered
fully earned and non-refundable) for each Product and for each New Product following approval for commercialisation for any Secondary
Indication and achievement of the events outlined in the table below (the “Secondary Indication Milestone Payments”).
The Secondary Indication Milestone Payments shall be paid only once per Product and once per New Product for each of the events
set forth in this Section 6.3.2(c), whether such milestone event is achieved by TGTX, its Affiliates, its Sublicensees (but only
in the event that the sublicense is executed subsequent to the NDA filing), or any Third Party acting on behalf of TGTX, its Affiliates,
its Sublicensees. No payment shall be due for any milestone event which is not achieved.

 

	 	Milestone(s)
    	 	 
	 	Milestone
    For Each Product  approved for Secondary Indication	 	 
	Approval	$
    * on US Launch	 	$
    *
	$
    * on EMA Launch	 	$
    *
	$
    * on Japan Launch	 	$
    *
	$
    * on each of China, Russia, Brazil Launch	 	$
    *
	 	Approval
    Subtotal	 	$
    *
	 	 	 	 

If the milestone
events in this Section 6.3.2(c) are achieved for a Product or a New Product following approval for a Secondary Indication, TGTX
shall be required to pay the corresponding approval milestone payments under this Section 6.3.2(c) for such Product or New Product
notwithstanding that an approval milestone was already paid under Section 6.3.2(b) for a Primary Indication.

 

 

*
Confidential material redacted and filed separately with the Commission.

 

    	20

    	 

    

 

d.         Non-Oncology
Indication Approval Milestone. TGTX shall pay the milestones payments set forth below (which, when paid, shall be considered
fully earned and non-refundable) for each Product or New Product following approval for commercialisation for any Non-Oncology
Indication and achievement of the events outlined in the table below (the “Non-Oncology Indication Milestone Payments”).
Each of the Non-Oncology Indication Milestone Payments shall be paid only once per Product and once per New Product for the events
set forth below, whether such milestone event is achieved by TGTX, its Affiliates, its Sublicensees (subject to Section 6.4 for
post NDA filing), or any Third Party acting on behalf of TGTX, its Affiliates, or its Sublicensees. No payment shall be due for
any milestone event which is not achieved.

 

	 	Milestone(s)
    	 	 
	 	Milestone
    For Each Product  approved for Non-Oncology 	 	 
	Approval	$
    * on US Launch	 	$
    *
	$
    * on EMA Launch	 	$
    *
	$
    * on Japan Launch	 	$
    *
	$
    * on each of China, Russia, Brazil Launch	 	$
    *
	 	Approval
    Subtotal	 	$
    *
	 	 	 	 

If the milestone
events in this Section 6.3.2(d) are achieved for a Product or a New Product following approval for a Non-Oncology Indication,
TGTX shall be required to pay the corresponding approval milestone payments under this Section 6.3.2(d) for such Product or New
Product notwithstanding that an approval milestone was already paid under Section 6.3.2(b) for a Primary Indication or under Section
6.3.2(c) for a Secondary Indication.

 

TGTX shall
provide Rhizen with written notice within ten (10) working days of the occurrence of any of the foregoing milestone events and
the relevant Milestone Payment is payable by TGTX to Rhizen within Fifteen (15) days of receipt of a corresponding invoice issued
by Rhizen. If TGTX determines that there is a reasonable likelihood of a particular milestone event being achieved on or about
a particular date, TGTX shall use reasonable efforts to provide advance notice thereof to Rhizen, which notice shall be provided
solely for Rhizen’ planning purposes and shall not be construed as a representation, warranty or covenant by TGTX that such
milestone event will occur when anticipated or at all.

 

	6.3.3:
    Royalties on Net Sales.    On a Product(s) by
    Product(s) basis, TGTX shall pay to Rhizen royalties based on the aggregate annual Net Sales of each Product(s) sold in the
    Territory at the rate shown in the table below during the Royalty Term for each country. 
	 

        Sales
        Royalties
	 

        *% of Net Sales up to $
        *
	 	 

        *%

	*% of Net Sales between
    $ * and $ *	 	*%
	*% of Net Sales greater
    than $ *	 	*%

         

 

*
Confidential material redacted and filed separately with the Commission.

 

    	21

    	 

    

 

6.4
Revenue Sharing

 

6.4.1 Sublicensing
Payments: On a product by product basis, TGTX shall pay to Rhizen a tiered percentage (ranging from *
%) of all Sublicensing Payments (the “Sublicensing Milestones”) received by TGTX and its Affiliates from
each Sublicensee throughout the term of the applicable Commercial Sublicensing Agreement, which percentage shall be equal to the
percentage set forth on the chart below corresponding to the number of Patients to whom the Product has been administered in any
Phase I, Phase II or Phase III Clinical Trial on the effective date of the Commercial Sublicensing Agreement (the “Applicable
Percentage”). Such payments shall be made to Rhizen within forty-five
(45) days following receipt by TGTX of any Sublicensing Payment made from and after the applicable event. For avoidance of doubt,
during the time that such sublicensing payments are made under this Section 6.4.1, the payments described under Section 6.3.2
and Section 6.3.3 shall not apply in the territory which has been sublicensed. If at any time a Commercial Sublicensing Agreement
is terminated or expires, Section 6.3.2 and Section 6.3.3 shall apply. “Patients dosed” in the table below refers
to the total patients dosed with the Product, on a product-by-product basis, after the Effective Date of this Licensing Agreement.

 

	 Event	Clinical
    stage(s)	%
    Share on Sublicensing 
	1	*
    patients dosed	*
	2	*
    patients dosed	*
	3	*
    patients dosed	*
	4	*
    patient dosed to NDA filing 	*

 

6.4.2 Royalties
on Sublicensee Royalties: On a product by product basis, TGTX shall pay to Rhizen the
Applicable Percentage of any Sublicensee Royalties received by TGTX and its Affiliates from each Sublicensee throughout
the term of the applicable Commercial Sublicensing Agreement. Such payments shall be made to Rhizen within forty-five (45) days
as of receipt by TGTX of the related Sublicensee Royalties. For avoidance of
doubt, during the time such Sublicensing Royalties are paid under this Section 6.4.2, the payments described in Section 6.3.3
shall not apply in the territory which has been sublicensed. If at any time a Commercial Sublicensing Agreement is terminated
or expires, Section 6.3.2 and Section 6.3.3 shall apply.

 

Royalties shall
be payable until expiration of the applicable Royalty Term for each country on a country-by-country
basis.

 

6.4.3 Royalties
on Net Sales: Subject to Section 6.5.1(a), in the event that TGTX and/or its Affiliates make direct sales of the Product
to Third Parties, then TGTX shall pay to Rhizen the amounts described in Section
6.3.3. For the sake of clarity, this Section 6.4.3 refers only to amounts received by TGTX not resulting from a sublicense agreement
with a Sublicensee and such Net Sale amounts shall be calculated pursuant to section 6.3.3.

 

6.4.4 Milestone
Payments: In the event that TGTX and/or its Affiliates sublicenses its rights under
this Agreement in any country where the applicable Commercial Sublicensing Agreement is entered into subsequent to the
filing of the NDA in such country,
then for the purpose of this Section 6.4 it will be considered as direct
sales of the Product, i.e., without involvement of a Sublicensee, and TGTX shall pay to Rhizen the milestones as defined
above in section 6.3.2. For avoidance of doubt, in such a case the payments under Section 6.4.1 and Section 6.4.2 shall not apply.

 

 

*
Confidential material redacted and filed separately with the Commission.

 

    	22

    	 

    

 

6.4.5 Royalties
on Net Sales: Subject to Section 6.5.1(a), in the event that TGTX and/or its
Affiliates sublicenses its rights under this Agreement in any country where the applicable
Commercial Sublicensing Agreement is entered into subsequent to filing the
NDA in such country, then for the purpose of this Section
6.4 it will be considered as direct sales of the Product, i.e., without involvement of a Sublicensee, and TGTX shall
pay to Rhizen the Royalties as defined above in Section 6.3.3. For avoidance of doubt, in such a case the payments under section
6.4.1 and Section 6.4.2 shall not apply.

 

6.5 Payments

 

6.5.1 Timing
of Royalty Payments and Sharing of Sublicensing Payments.

 

(a) Royalties
on Net Sales pursuant to Section 6.3.3 shall be paid by TGTX to Rhizen quarterly within forty-five (45) days after the end of
calendar quarter in which such Net Sales are made (as determined by the date of invoice or billing). Simultaneously with such
payment, TGTX shall provide a report to Rhizen of its calculation of such Royalties, in sufficient detail, including the amounts
of gross revenues and applicable deductions (the “Quarterly Royalty Report”). Such Royalties shall be subject to a
true-up adjustment to take into account deductions under the definition of Net Sales either (A) allowed during a calendar quarter
that were not accrued during such calendar quarter, or (B) accrued during a calendar quarter but not taken or later subject to
a reversal following the end of such calendar quarter (each of (A) and (B), a “True-up Adjustment”). Each Quarterly
Royalty Report provided by TGTX shall set forth the amount of any True-up Adjustment applicable to any prior calendar quarter.

 

(b) Royalties
on Sublicensee Royalties shall be paid by TGTX to Rhizen quarterly within forty-five (45) days after the
end of each quarter based upon Sublicensee Royalties received by TGTX or its Affiliate
during such quarter. If such Sublicensee Royalties are significantly overdue, then upon Rhizen’ request, the Parties
agree to discuss the matter in good faith.

 

(c) Rhizen’s
share of Sublicensing Payments shall be paid by TGTX to Rhizen within forty-five
(45) days after such Sublicensing Payments are received by TGTX or its Affiliate..

 

6.5.2 All payments
to Rhizen hereunder shall be made using the bank details provided by Rhizen. All payments to Rhizen shall be made in US dollars.
If payments of Sublicensee Royalties, Net Sales, or Sublicensing Payments are made in another currency other than US dollars,
TGTX shall convert them into US dollars for the purpose of the calculation of Royalties and sharing of Sublicensing Payments by
applying the average interbank exchange rate as published by (OANDA/US treasury) for the last day of each month within the calendar
quarter for which payment to Rhizen is due. All costs associated with making payments to Rhizen, including the cost of wire transfers,
shall be paid by TGTX and shall not be deducted from the payments to Rhizen.

 

    	23

    	 

    

 

6.5.3 TGTX
shall (and shall require its Affiliates to) prepare and maintain complete and accurate books and records regarding Net Sales (including
gross sales and applicable deductions from gross sales), Sublicensee Royalties, Sublicensing Payments and Royalties due hereunder.
Rhizen shall have the right to have such books and records reasonably inspected
by an independent certified auditor selected by Rhizen and accepted by TGTX, whose acceptance shall not be unreasonably withheld,
to confirm Net Sales (including gross sales and applicable deductions from gross sales), Sublicensee Royalties, Sublicensing Payments
and Royalties due hereunder. Such auditor will execute a written confidentiality agreement with TGTX and will disclose to Rhizen
only such information as is reasonably necessary to provide Rhizen with information regarding any actual discrepancies between
the amounts reported or paid and the amounts payable under this Agreement. Such auditor will send a copy of its report to TGTX
within fifteen (15) days of delivery of such report to Rhizen. Such report will include the methodology and calculations used
to determine the results. Prompt adjustments shall be made by the Parties to reflect the results of such audit. Records to be
available under an inspection shall include all relevant documents pertaining to payments specified above, including all relevant
documents received by TGTX from Sublicensees. Rhizen shall bear the fees and expenses of such inspection, provided that, if an
underpayment of more than Five percent (5%) of the payments due for any calendar year is discovered in any inspection, then TGTX
and or its affiliates shall bear all fees and expenses of that inspection within thirty (30) days after receipt of invoice from
Rhizen.

 

6.5.4 Without
limiting any other rights or remedies available to Rhizen, TGTX shall pay Rhizen interest on any payments that are not paid on
or before 15 days from the due date at the British Bankers Association’s one
month LIBOR Rate for United States Dollar deposits calculated from the due date to the date paid in full.

 

6.5.5 In the
event TGTX fails to pay overdue amounts to Rhizen within the due date under this Section 6.5, Rhizen shall have the right to terminate
this Agreement upon forty-five (45) days’ prior written notice to TGTX pursuant to Section 12.4, unless TGTX has cured such
failure to pay by the end of such forty-five (45) day period.

 

6.5.6 TGTX
shall make payments to Rhizen under this Agreement withholding any taxes that may be due with respect to such payments to the
extent that such withholding is required by applicable law. If any taxes are required to be withheld by TGTX, then TGTX shall
(a) deduct such taxes from the payment made to Rhizen, (b) timely pay the taxes to the proper taxing authority, and (c) send proof
of such tax payments to Rhizen and certify receipt of such payment by the applicable tax authority within sixty (60) days following
such tax payment

 

7 INTELLECTUAL
PROPERTY

 

7.1 Ownership
of Intellectual Property Rights and Inventions

 

7.1  Ownership
of Inventions.

The
Rhizen Intellectual Property Rights shall at all times be and remain the sole property of Rhizen,
subject to any limitation on the transfer of such rights contained herein.

 

Any
new invention pertaining to the product made alone or jointly by the parties shall be owned by both Parties (“Joint Inventions”),
unless otherwise determined by the JSC to be owned by solely by either Party (a “Sole Invention”).

 

    	24

    	 

    

 

Further,
the JSC shall determine:

a)
If either party is eligible for any payment or consideration in lieu of the invention and/or royalty; or

 

b)
If the licensing of such Joint Inventions by either Party to a Third Party could have a material adverse effect on the Product
or the Development or Commercialization of the Product, and if so determined such Party will not be able to consummate such Third
Party licensing.

 

Inventorship
shall be determined by the JSC in accordance with U.S. patent Laws. Sole Inventions
owned by TGTX and TGTX’s interest in all Joint Inventions shall be included in the TGTX Intellectual Property Rights.
Sole Inventions owned by Rhizen and Rhizen’s interest in all Joint Inventions shall be included in the Rhizen Intellectual
Property Rights.

 

7.2
Disclosure of Inventions. Each Party shall promptly disclose to the other any invention disclosures, or other similar documents,
submitted to it by its employees, agents or independent contractors describing inventions that may be either Sole Inventions or
Joint Inventions, and all Information relating to such inventions. Sole Inventions and Joint Inventions required or deemed useful
by the JSC for the development or commercialization of the Product, shall automatically be included in this Agreement and available
for use by the Parties in the Territory.

 

7.3 Prosecution
of Patents.

 

		(a)	Rhizen
                                         Patents Other than Joint Patents. Except as otherwise provided in this Section 7.3(a),
                                         Rhizen shall have the sole right, authority and obligation to file, prosecute and maintain
                                         the Rhizen Patents (other than Joint Patents which shall be prosecuted and maintained
                                         in accordance with Section 7.3(b)) in the Territory and on a worldwide basis. Rhizen
                                         shall provide TGTX reasonable opportunity to review and comment on such prosecution efforts
                                         regarding such Rhizen Patents in the Territory. Rhizen shall provide TGTX with a copy
                                         of material communications from any patent authority in the Territory regarding such
                                         Rhizen Patents, and shall provide TGTX with drafts of any material filings or responses
                                         to be made to such patent authorities a reasonable amount of time in advance of submitting
                                         such filings or responses. Notwithstanding the foregoing, if Rhizen desires to abandon
                                         or not maintain any Patent within such Rhizen Patents in the Territory, then Rhizen shall
                                         provide TGTX with thirty (30) days prior written notice of such desire (or such longer
                                         period of time as reasonably necessary to allow TGTX to assume such responsibilities)
                                         and, if TGTX so requests, shall provide TGTX with the opportunity to prosecute and maintain
                                         such Patent in the Territory in place of Rhizen. If TGTX desires Rhizen to file, in the
                                         Territory, a patent application that claims priority from a Patent within the Rhizen
                                         Patents, other than a Joint Patent, in the Territory, TGTX shall provide written notice
                                         to Rhizen requesting that Rhizen file such patent application in the Territory. If TGTX
                                         provides such written notice to Rhizen, Rhizen shall either (i) file and prosecute such
                                         patent application and maintain any patent issuing thereon in the Territory or (ii) notify
                                         TGTX that Rhizen does not desire to file such patent application and provide TGTX with
                                         the opportunity to file and prosecute
                                         such patent application and maintain any patent issuing thereon in the Territory in place
                                         of Rhizen

  

    	25

    	 

    

 

		(b)	Joint
                                         Patents. Except as otherwise provided in this Section 7.3(b), the JSC shall entrust
                                         one Party with the right and authority, to prosecute and maintain the Joint Patents on
                                         a worldwide basis at its sole discretion herein referred to as an “Entrusted
                                         Party” (subject to this Section 7.3(b)). The Entrusted Party shall provide
                                         the other party reasonable opportunity to review and comment on such prosecution efforts
                                         regarding such Joint Patents. The Entrusted Party shall provide the other party with
                                         a copy of material communications from any patent authority regarding such Joint Patents,
                                         and shall provide the other party with drafts of any material filings or responses to
                                         be made to such patent authorities a reasonable amount of time in advance of submitting
                                         such filings or responses. If one Party (the “First Party”) determines in
                                         its sole discretion to abandon or not maintain any Patent within the Joint Patents anywhere
                                         in the world, then such Party shall provide the other Party (the “Second Party”)
                                         with thirty (30) days’ prior written notice of such determination (or such longer
                                         period of time reasonably necessary to allow the other party to assume such responsibilities)
                                         and shall provide the Second Party with the opportunity to prosecute and maintain such
                                         Patent at the Second Party’s sole expense, and if the Second Party so requests,
                                         the First Party shall assign such Patent to the Second Party (if the Second Party is
                                         Rhizen, such Patent shall be included in the Rhizen Patents or if the Second Party is
                                         TGTX, in which case such patent will be included in the TGTX Patents).  If one Party
                                         (the “First Party”) desires to file, in a particular jurisdiction, a patent
                                         application that claims priority from a Patent within the Joint Patents, the First Party
                                         shall provide written notice to the other Party (the “Second Party”) of such
                                         desire. Within fifteen (15) days of such written notice, the Second Party shall provide
                                         written notice to the First Party as to whether the Second Party agrees to file a patent
                                         application in such jurisdiction or not. In the event the Second Party agrees to such
                                         a filing, the Entrusted Party shall file such patent application in such jurisdiction.
                                         In the event the Second Party does not desire to file in such jurisdiction, the Second
                                         Party shall (i) provide the First Party with the opportunity to file and prosecute such
                                         patent application and maintain any patent issuing therefrom, and (ii) assign such patent
                                         application or a right to file such patent application to the First Party; and the First
                                         Party may file such patent application in such jurisdiction at its sole expense (in which
                                         case such Patent shall be included in the respective Party’s Patents).

 

		(c)	Cooperation
                                         in Prosecution. Each Party shall provide the other Party all reasonable assistance
                                         and cooperation in the Patent prosecution efforts provided above in this Section 7.3,
                                         including providing any necessary powers of attorney and executing any other required
                                         documents or instruments for such prosecution.

 

		(d)	Costs
                                         of Prosecution. The costs to prosecute and maintain the Rhizen Patents related to
                                         the Product shall be borne by Rhizen. The costs to prosecute and maintain the Joint Patents
                                         related to the Product shall be borne equally by Rhizen and TGTX. The costs to prosecute
                                         and maintain the TGTX Patents related to the Product shall be borne by TGTX. 

 

		7.4	Infringement
                                         of Patents by Third Parties.

		(a)	Notification.
                                         Each Party shall promptly notify the other Party in writing of any existing or threatened
                                         infringement of the Rhizen Patents, Joint Patents or TGTX Patents of which it becomes
                                         aware, and shall provide evidence in such Party’s possession demonstrating such
                                         infringement.

 

    	26

    	 

    

  

(b)
Infringement of Patents in the Territory.

 

		(i)	If
                                         a Party becomes aware that a Third Party infringes any Rhizen Patent, TGTX Patent, or
                                         Joint Patent in the Territory by making, using, importing, offering for sale or selling
                                         the Product or any similar PI3Kδ selective inhibitor covered by any of such Patents
                                         (such activities, “Product Infringement”), then such Party shall so
                                         notify the other Party as provided in Section 7.4 (a), which such notice shall include
                                         all information available to the notifying Party regarding such alleged infringement.
                                         

 

		(ii)	In
                                         the Territory, TGTX shall have the first right, but not the obligation, to bring an appropriate
                                         suit or other action against any person or entity engaged in such Product Infringement,
                                         subject to Section 7.4(b)(iii) below, the cost and expense will be borne by TGTX. TGTX
                                         shall have a period of one hundred twenty (120) days (or shorter period, if required
                                         by the nature of possible proceeding) after notification by Rhizen or providing notification
                                         to Rhizen pursuant to Section 7.4(a), to elect to so enforce such Patent. In the event
                                         TGTX does not so elect, it shall so notify Rhizen in writing during such one hundred
                                         twenty (120) day time period (or the above-mentioned shorter period), and Rhizen shall
                                         have the right, but not the obligation, to commence a suit or take action to enforce
                                         the applicable Patent against such Third Party perpetrating such Product Infringement
                                         at its sole cost and expense (except as otherwise expressly provided in this Section
                                         7.4(b)(ii)). Each Party shall provide to the Party enforcing any such rights under this
                                         Section 7.4(b)(ii) reasonable assistance in such enforcement, at such enforcing Party’s
                                         request, including joining such action as a party plaintiff if required by applicable
                                         Law to pursue such action. The enforcing Party shall keep the other Party regularly informed
                                         of the status and progress of such enforcement efforts, and shall reasonably consider
                                         the other Party’s comments on any such efforts. Any recoveries obtained from a
                                         suit or an action commenced by TGTX hereunder shall first be applied to the recovery
                                         of expenses incurred by TGTX or Rhizen (if any) in bringing the suit or action and the
                                         remaining amounts, if any, shall be deemed additional Net Sales; provided, further, however,
                                         if Rhizen proceeds with the enforcement after TGTX decides not to move forward, then
                                         any amounts recovered shall belong solely to Rhizen. 

 

		(iii)	The
                                         Party not bringing an action with respect to Product Infringement in the Territory under
                                         Section 7.4(b) shall be entitled to separate representation in such matter by counsel
                                         of its own choice and at its own expense, but such Party shall at all times cooperate
                                         fully with the Party bringing such action. Additionally, the Party not bringing an action
                                         under this Section 7.4(b) may have an opportunity to participate in such action to the
                                         extent that the Parties may mutually agree at the time the other Party elects to bring
                                         an action hereunder.

 

    	27

    	 

    

  

		(e)	Settlement.
                                         TGTX shall not settle any claim, suit or action that it brings under this Section 7.4
                                         involving Rhizen Patents (excluding Joint Patents) in any manner that would have a materially
                                         adverse impact on Rhizen Patents anywhere in the world, or that would materially limit
                                         or restrict the ability of either Party to manufacture, use, sell, offer for sale or
                                         import the Product anywhere in the world, without the prior written consent of Rhizen.
                                         Rhizen shall not settle any claim, suit or action that it brings under this Section 7.4
                                         involving TGTX Patents (excluding Joint Patents) in any manner that would negatively
                                         impact the TGTX Patents or that would limit or restrict the ability of either Party to
                                         manufacture, use, sell, offer for sale or import the Product anywhere in the world, without
                                         the prior written consent of TGTX. Neither Party shall settle any claim, suit or action
                                         that it brings under this Section 7.4 involving Joint Patents in any manner that would
                                         negatively impact the Joint Patents or that would limit or restrict the ability of either
                                         Party to manufacture, use, sell, offer for sale or import the Product anywhere in the
                                         world, without the prior written consent of such other Party.

 

		(f)	Rights
                                         to Intellectual Property Outside the Territory.  

 

		(i)	TGTX
                                         hereby grants Rhizen a perpetual, exclusive, royalty-free license, with the right to
                                         sublicense, to the Joint Patents and a perpetual, non-exclusive, royalty-free license
                                         to the Joint Know-How to make, have made, use, sell, offer for sale, and import the Product
                                         outside the Territory.  Outside the Territory, Rhizen shall have the right, but
                                         not the obligation, at Rhizen’s sole expense, to bring an appropriate suit or other
                                         action against any person or entity engaged in Product Infringement of the Joint Patents.
                                         TGTX shall provide to Rhizen when enforcing any such rights under this Section 7.4(f)
                                         reasonable assistance in such enforcement, at Rhizen’s request and cost, including
                                         joining such action as a party plaintiff if required by applicable Law to pursue such
                                         action. 

 

		(ii)	The
                                         Parties agree that in the event Rhizen desires to use the TGTX Intellectual Property
                                         Rights, other than the Joint Patents and the Joint Know-How, for any purpose outside
                                         of the Territory, then Rhizen shall pay such fair market value royalties and/or fees
                                         to TGTX that the Parties determine by future written agreement. Each Party agrees to
                                         negotiate in good faith to execute an agreement regarding the subject matter of this
                                         paragraph. 

 

		(iii)	For
                                         the purpose of this Section 7.4(f), TGTX Intellectual Property Rights shall exclude any
                                         rights related to Ublituximab.

 

8 REPRESENTATIONS,
WARRANTIES AND CERTAIN COVENANTS 

 

8.1 Each Party
represents, warrants and covenants to the other that:

 

		(i)	It is a company or corporation
duly organized, validly existing, and in good standing under the Laws of the jurisdiction in which it is incorporated, and has
full corporate power and authority and the legal right to own and operate its property and assets and to carry on its business
as it is now being conducted and as contemplated in this Agreement, including, without limitation, the right to grant the licenses
granted by it hereunder;

 

    	28

    	 

    

  

		(ii)	As of the Effective Date,
(i) it has the corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder;
(ii) it has taken all necessary corporate action on its part required to authorize the execution and delivery of the Agreement
and the performance of its obligations hereunder; and (iii) the Agreement has been duly executed and delivered on behalf of such
Party, and constitutes a legal, valid, and binding obligation of such Party that is enforceable against it in accordance with
its terms. The execution, delivery and performance of this Agreement by it does not conflict with any agreement or instrument,
oral or written, to which it is a party or by which it may be bound;

 

		(iii)	It has not granted, and shall
not grant, any right to any Third Party which would conflict with the rights granted to the other Party hereunder; and

 

		(iv)	It is not a party to any agreement
that would prevent it from granting the rights granted to the other Party under this Agreement or performing its obligations under
this Agreement. The execution, delivery and performance of this Agreement shall not violate, conflict with or constitute a default
under any agreement (including its corporate charter or other organizational documents) to which it is a party or to which it
may be bound, or to its best knowledge, any applicable Laws or order of any court or other tribunal.

 

8.2 Rhizen
represents and warrants and covenants to TGTX that as of the Effective Date:

 

		(i)	All rights pertaining to the
Rhizen Patents are owned by Rhizen;

 

		(ii)	The Rhizen Patents are not
subject to any encumbrance, lien or claim or ownership by any Third Party that is inconsistent with the rights and licenses granted
to TGTX hereunder;

 

		(iii)	Rhizen owns or possesses adequate
right, title and interest in the Rhizen Intellectual Property Rights to grant the license thereto to TGTX as provided in this
Agreement;

 

		(iv)	No claim or litigation has
been brought, or is threatened to be brought, by any person or entity (A) alleging that any of the Rhizen Patents in the Territory
is invalid or unenforceable, (B) relating to the Rhizen Intellectual Property, or (C) alleging that use of the Rhizen Intellectual
Property in the Territory infringes or otherwise conflicts or interferes with any intellectual property or proprietary right of
any Third Party;

 

		(v)	No Third Party has infringed
or misappropriated any Rhizen Intellectual Property by making, using, importing, offering for sale or selling the Product and,
as of the Effective Date, there is no actual or threatened infringement or misappropriation of the Rhizen Technology by any Third
Party by making, using, importing, offering for sale or selling the Product;

 

		(vi)	Neither A) TGTX’s exercise
of its rights hereunder with respect to the Rhizen Intellectual Property, nor (B) TGTX’s Development or Commercialization
of the Product in the Territory, shall infringe any valid and enforceable Patent of any Third Party;

 

    	29

    	 

    

  

		(vii)	This Agreement is consistent
with all Third Party license agreements in all respects and does not conflict with, violate, breach or otherwise give rise to
a default by Rhizen under, any term of any Third Party license agreement;

 

		(viii)	   Rhizen has obtained any and
all consents, if any, required from Third Parties for Rhizen to enter into this Agreement and to grant to TGTX the licenses and
other rights provided herein and has provided a copy of such consents to TGTX;

 

		(ix)	Rhizen has not received any
written notice from any Third Party claiming that the manufacture, use, sale, or importation of the Compound or Product by Rhizen
prior to the Effective Date infringed any patent owned or controlled by any Third Party;

 

		(x)	Rhizen has not granted any
license or other right to any Third Party regarding the Product and/or the Rhizen Intellectual Property Rights;

 

		(xi)	Rhizen has not received any
grant from or entered into any agreement with any government and/or any of its subdivisions or federal governmental bodies, or
any other governmental bodies, regarding the Compound and/or the Rhizen Intellectual Property Rights; and

 

		(xii)	  All products and materials
supplied by Rhizen to TGTX pursuant to this Agreement shall be manufactured, handled and stored by Rhizen or its Third Party contract
manufacture(s): (i) in accordance with the agreed upon specification and (ii) in compliance with applicable Laws and regulations,
including without limitation, the GMP requirements.

		8.3.	Representations,
                                         Warranties, and Covenants of TGTX.

 

8.3.1
TGTX agrees that all of its activities, and the activities of its Affiliates and Sublicensees related to its use of the Rhizen
Patents and Rhizen Know-How and all Development and Commercialization of the Product including the transport, storage, sale and
promotion thereof, pursuant to this Agreement shall comply with all applicable legal and regulatory requirements. TGTX, its Affiliates,
and Sublicensees shall not engage in any activities that use the Rhizen Patents and/or Rhizen Know-How in a manner that is outside
the scope of the license rights granted to TGTX hereunder. TGTX represents and warrants that it will comply with the U.K. Bribery
Act, the United States Foreign Corrupt Practices Act and any and all other applicable Laws prohibiting corruption or bribery (collectively
referred to as the “Anti-Corruption Laws”).

 

8.3.2
  TGTX represents, warrants, and covenants that (i) the issuance of the Shares has been duly authorized by all necessary
corporate action; (ii) upon issuance, the Shares will be validly issued, fully paid and nonassessable, free and clear of all liens,
encumbrances, restrictions (including under the Securities Act), charges, security interests, rights of first refusal and preemptive
rights; and (iii) TGTX shall reserve from its authorized and unissued shares of Common Stock, a sufficient number of shares of
Common Stock to issue Rhizen the shares in accordance with Article 6 hereof.

 

8.4 No Other
Representations or Warranties: Except as expressly set forth in this Agreement, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL
WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR
A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING,
USAGE OR TRADE PRACTICES

 

    	30

    	 

    

  

9 INDEMNIFICATION
AND INSURANCE

 

9.1 TGTX shall
indemnify, defend, and hold harmless Rhizen and its Affiliates and their respective directors, officers, employees and agents
(each, a “Rhizen Indemnitee”) from and against any and all claims, suits, actions, demands, liabilities, expenses
and/or loss, including reasonable legal expense and attorneys’ fees (collectively, “Losses”), to which
any Rhizen Indemnitee may become subject as a result of any claim, demand, action or other proceeding (each, a “Claim”)
by any Third Party to the extent such Losses arise out of or result from (a) any breach by TGTX of its representations, warranties,
covenants or obligations in this Agreement or (b) the gross negligence or wilful misconduct of TGTX, its Affiliates or Sublicensees;
except, in each case, to the extent such claim is caused by a breach of this Agreement by Rhizen or the gross negligence or wilful
misconduct of Rhizen.

 

9.2 Rhizen
shall indemnify, defend, and hold harmless TGTX and its Affiliates and their respective directors, officers, employees and agents
(each, a “TGTX Indemnitee”) from and against any and all Losses to which any TGTX Indemnitee may become subject
as a result of any Claim by a Third Party to the extent such Losses arise out of or result from (a) any breach by Rhizen of its
representations, warranties, covenants or obligations in this Agreement, or (b) the gross negligence or wilful misconduct of Rhizen
or its Affiliates; except, in each case, to the extent such claim is caused by a breach of this Agreement by TGTX or the gross
negligence or wilful misconduct of TGTX.

 

9.3 For purposes
of Sections 9.1 and 9.2, the Rhizen Indemnitee or TGTX Indemnitee (the “Indemnified Party”) shall give prompt
written notice to the other Party (the “Indemnifying Party”) of any claims, suits or proceedings by Third Parties
which may give rise to any claim for which indemnification may be required under Section 9.1 or 9.2; provided, however,
that failure to give such notice shall not relieve the Indemnifying Party of its obligation to provide indemnification hereunder
except, if and to the extent that such failure materially and adversely affects the ability of the Indemnifying Party to defend
the applicable claim, suit or proceeding. The Indemnifying Party shall be entitled to assume the defence and control of any such
claim at its own cost and expense; provided, however, that the Indemnified Party shall have the right to be represented by its
own counsel at its own cost in such matters. Neither the Indemnifying Party nor the Indemnified Party shall settle or dispose
of any such matter in any manner which would adversely affect the rights or interests of the other Party (including the obligation
to indemnify hereunder) without the prior written consent of the other Party, which shall not be unreasonably withheld or delayed.
Each Party shall reasonably cooperate with the other Party and its counsel in the course of the defence of any such suit, claim
or demand, such cooperation to include without limitation using reasonable efforts to provide or make available documents, information
and witnesses.

 

9.4 At and
during such time as TGTX, its Affiliates, or its Sublicensees, begins clinical testing, sale or distribution of Products, TGTX
shall (and shall require its Affiliates and Sublicensees to) at its sole expense, procure and maintain commercially reasonable
insurance policies as would be maintained by similarly situated pharmaceutical companies consistent with the current industry
standards for similar products, and compliant with any applicable law or regulation.

 

    	31

    	 

    

  

9.5 EXCEPT
WITH RESPECT TO A BREACH OF SECTION 10 HEREOF, IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR INCIDENTAL, CONSEQUENTIAL, INDIRECT,
PUNITIVE OR SPECIAL DAMAGES OF THE OTHER PARTY ARISING OUT OF OR RELATED TO THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF
LIABILITY EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

 

10 CONFIDENTIALITY

 

10.1 Except
to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, each Party agrees that, for
the Term and until the later of (i) the tenth (10th) anniversary of the Effective Date, or (ii) five (5) years
after the expiration or termination of the Term, it shall keep confidential and shall not publish or otherwise disclose, and shall
not use for any purpose other than as as provided for in this Agreement, any Confidential Information furnished to it by the other
Party pursuant to this Agreement except for that portion of such information or materials that the receiving Party can demonstrate
by competent written proof:

		(a)	was
                                         already known to the receiving Party or its Affiliate, other than under an obligation
                                         of confidentiality to the disclosing Party, at the time of disclosure by the other Party,
                                         as evidenced by written documentation;

		(b)	was
                                         generally available to the public or otherwise part of the public domain at the time
                                         of its disclosure to the receiving Party;

		(c)	became
                                         generally available to the public or otherwise part of the public domain after it disclosure
                                         and other than through any act or omission of the receiving Party in breach of this Agreement;

		(d)	was
                                         disclosed to the receiving Party or its Affiliate by a Third Party without obligations
                                         of confidentiality with respect thereto; or

		(e)	was
                                         independently discovered or developed by the receiving Party or its Affiliate without
                                         the aid, application, or use of Confidential Information of the other Party, as evidenced
                                         by written documentation; provided, however, that this exception shall not apply to information
                                         or materials consisting of data and results generated or resulting from Development activities
                                         with respect to the Product, which information and materials shall be deemed Confidential
                                         Information of the Party who has developed such information or materials regardless of
                                         whether such information and materials were independently discovered or developed by
                                         the receiving Party or its Affiliate.

 

10.2 Authorized
Disclosure.  Each Party may disclose Confidential Information belonging to the other Party to the extent such disclosure
is reasonably necessary in the following situations:

		(a)	filing
                                         or prosecuting Patents as permitted in this Agreement;

		(b)	regulatory
                                         submissions and other filings with Governmental Authorities, including filings with the
                                         Securities and Exchange Commission;

		(c)	prosecuting
                                         or defending litigation or other proceedings or regulatory actions;

		(d)	complying
                                         with applicable Laws;

 

    	32

    	 

    

  

		(e)	disclosure
                                         to its employees, agents, and consultants, and any Third Parties  (and potential
                                         licensees and) with which a Party is Developing or Commercializing the Product) only
                                         on a need-to-know basis and solely as necessary in connection with the performance of
                                         this Agreement, provided that in each case the recipient of such Confidential Information
                                         must agree to be bound by similar obligations of confidentiality and non-use at least
                                         as equivalent in scope as those set forth in this Article 10 prior to any such disclosure;
                                         and

		(f)	disclosure
                                         of the material financial terms of this Agreement to any bona fide potential investor,
                                         investment banker, acquiror, merger partner, or other potential financial partner; provided
                                         that in connection with such disclosure, the disclosing Party shall use all reasonable
                                         efforts to inform each recipient of the confidential nature of such Confidential Information
                                         and shall cause each recipient of such Confidential Information to treat such Confidential
                                         Information as confidential. 

 

Notwithstanding
the foregoing, in the event the Receiving Party is required to make a disclosure of Confidential Information pursuant to Section
10.2(c) or 10.2(d), the Receiving Party shall, except where not permitted by applicable Law, give reasonable advance notice to
the Disclosing Party of such required disclosure and, at the Disclosing Party’s request and expense, cooperate fully with
the Disclosing Party’s lawful efforts to contest such required disclosure, to minimize the scope of such required disclosure,
and/or to obtain a protective order or other confidential treatment of the Confidential Information required to be disclosed.
In any event, the Receiving Party agrees to take all reasonable action to avoid disclosure of Confidential Information hereunder

 

10.3 The Parties
agree that the terms of this Agreement shall be treated as Confidential Information by both Parties.

 

10.4 The Parties
acknowledge that each Party may desire or be required to issue press releases or to make other public disclosures relating to
this Agreement or its terms. The Parties agree to consult with each other reasonably and in good faith with respect to the text
and timing of such press releases or other public disclosures prior to the issuance thereof, provided that a Party may not unreasonably
withhold consent to such releases, and that either Party may issue such press releases as it determines, based on advice of counsel,
are reasonably necessary to comply with laws or regulations. In addition, following an initial press release announcing this Agreement,
each Party shall be free to disclose, without the other Party’s prior written consent, the existence of this Agreement,
the identity of the other Party and those terms of this Agreement which have already been publicly disclosed in accordance herewith.

 

10.5 Subject
to Section 10.4, TGTX shall not use the name “Rhizen” nor any variation or adaptation thereof, nor any trademark,
tradename or other designation owned by Rhizen or its Affiliates, nor the names of any of its officers, employees or agents, for
any purpose without the prior written consent of the other Party in each instance, except that TGTX may state that it has licensed
from Rhizen one or more of the patents and/or applications within the Rhizen Patents, and TGTX may use Rhizen’s logo on
TGTX’s corporate website and corporate presentation materials for such purpose, subject to Rhizen’s prior review and
approval (not to be unreasonably withheld) of TGTX’s proposed use thereof.

 

    	33

    	 

    

  

10.6 Subject
to Section 10.4, Rhizen shall not use the name of “TGTX” or its Affiliates nor any variation or adaptation thereof,
nor any trademark, tradename or other designation owned by TGTX or its Affiliates, nor the names of any of its officers, employees
or agents, for any purpose without the prior written consent of the other Party in each instance, except that Rhizen may state
that it has licensed to TGTX one or more of the patents and/or applications within the Rhizen Patents, and Rhizen may use TGTX’s
logo on Rhizen’s corporate website and corporate presentation materials for such purpose, subject to TGTX’s prior
review and approval (not to be unreasonably withheld) of Rhizen’s proposed use thereof.

 

10.7Each
Party recognizes that the publication by TGTX of Data and other information regarding Compounds and Products, such as by public
oral presentation, manuscript or abstract, may be beneficial to both Parties provided such publications are subject to reasonable
controls to protect Confidential Information. Accordingly, Rhizen shall have the right to review and comment on any material proposed
for public oral presentation or publication by TGTX that includes Data or other results of preclinical or clinical development
of the Compound or any Product and/or includes Confidential Information of Rhizen. Before any such material is submitted for publication,
TGTX shall use reasonable efforts to deliver a complete copy to Rhizen at least thirty (30) days prior to submitting the material
to a publisher or initiating any other disclosure. Rhizen shall review any such material and give its comments to TGTX within
ten (10) days of the delivery of such material to Rhizen. With respect to public oral presentation materials and abstracts, Rhizen
shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable
to TGTX with appropriate comments, if any, but in no event later than ten (10) days from the date of delivery to Rhizen. TGTX
shall comply with Rhizen’s request to delete references to Rhizen’s Confidential Information in any such material.
In addition, if any such publication contains patentable subject matter, then at Rhizen’s request, TGTX shall either delete
the patentable subject matter from such publication or delay any submission for publication or other public disclosure for a period
of up to an additional sixty (60) days so that appropriate patent applications may be prepared and filed.

 

10.8 Subject
to Section 10.7, TGTX and its contractors, including without limitation clinical research organizations, shall have the right
to publish results of all clinical trials of the Compound or any Product on TGTX’s clinical trial register, and such publication
will not be a breach of the confidentiality obligations provided in this Article 10.

 

10.9 All obligations
of confidentiality and non-use imposed under this Article 10 shall expire ten (10) years after the date of termination or expiration
of this Agreement

 

11 EXPIRY OF
THE AGREEMENT; CONSEQUENCES OF EXPIRY 

 

11.1 Unless
terminated earlier pursuant to Article 12 or other mutual written agreement, this Agreement shall commence upon the Effective
Date and shall expire, on a country-by-country basis on the expiration of the Royalty Term (the “Royalty Term”).

 

12 TERMINATION

 

12.1 
TGTX Termination with Cause: TGTX may terminate this Agreement at any time for Cause upon ninety (90) days’ prior
written notice to Rhizen.

 

12.2 TGTX
Termination: TGTX may terminate this Agreement at any time for any reason upon ninety (90) days’ prior written notice
to Rhizen.

 

    	34

    	 

    

  

12.3 Rhizen
Termination for TGTX Diligence Failure: If TGTX does not correct a failure to use Diligent Efforts within the applicable period
specified in, or determined in accordance with, Section 3.2.5 (b) (a “Diligence Failure”), Rhizen shall
have the right to terminate this Agreement on ninety (90) days’ written notice to TGTX unless TGTX cures such Diligence
Failure before the end of such ninety (90) day period.

 

12.4 Termination
for Material Breach: Each Party shall have the right to terminate this Agreement upon ninety (90) days’ (or forty-five
(45) days’ in the case of failure to make payment of amounts due hereunder) prior written notice to the other Party in the
event of the material breach of any term or condition of this Agreement by the other Party, unless the breaching Party has cured
such breach by the end of the applicable cure period; provided, however, that:

 

(a) this Section
12.4 shall not apply to any Diligence Failure by TGTX (in which case, Rhizen’ termination right shall be as set forth in
Section 12.3); and

 

(b) any right
to terminate under this Section 12.4 shall be stayed and the cure period shall be stopped in the event that, during any cure period,
the Party alleged to have been in material breach shall have initiated dispute resolution in accordance with Article 20 with respect
to the alleged breach, which stay and stopping shall last so long as the dispute resolution proceedings are ongoing.

 

13 CONSEQUENCES
OF TERMINATION

 

13.1 In the
event of

 

(A) termination
of this Agreement by TGTX pursuant to Section 12.1 or 12.2:

 

(a)
The license granted by Rhizen to TGTX under Section 2.1 shall terminate and revert to Rhizen on the effective date of termination.

 

(b)
Rhizen shall have the right, exercisable upon written notice by Rhizen to TGTX given within sixty (60) days after the effective
date of such termination, to obtain, and effective upon such notice, TGTX shall, and it hereby does, grant to Rhizen, a perpetual,
exclusive, worldwide, royalty-bearing license, with the right to sublicense, under TGTX Intellectual Property Rights (which, for
purposes of this Section 13.1 shall not include the Joint Patents or the Joint Know-How) solely to develop, make, have made, use,
sell, offer for sale, have sold and import the Compound and Products in the Field of Use, subject to the terms and conditions
set forth below in subparagraph (c). TGTX shall provide to Rhizen when enforcing any such rights under this Section 13.1(A)(b)
reasonable assistance in such enforcement, at Rhizen’s request and cost, including joining such action as a party plaintiff
if required by applicable Law to pursue such action. In consideration for such exclusive license, Rhizen shall pay to TGTX a royalty
based on the fair market value of such license.  The royalty will be negotiated in good faith by the Parties within fifteen
(15) days following the effective date of the termination. If the Parties cannot agree on the terms of the royalty, the parties
will select a disinterested Third Party to determine the fair market value of the license (the “Appraiser”). 
Once the Appraiser is selected, the Appraiser shall be instructed to furnish a written appraisal within sixty (60) days of it
selection. In the event of termination pursuant to Section 12.2, TGTX shall bear the Appraiser’s reasonable costs and expenses,
otherwise such costs and expenses will be shared equally by the Parties.  The fair market value royalty will be paid out
of Rhizen’s gross profits following the first commercial sale of the Product, and which gross profits will be based on all
amounts paid to Rhizen from its sublicensing or from sales directly or indirectly in the particular country or Territory. The
term of such royalty will expire on the expiration of the last to expire issued Valid Claim within the TGTX Patents covering the
Product in the particular country or Territory.

 

    	35

    	 

    

  

TGTX
shall, and it hereby does, upon such Termination grant to Rhizen, (i) a perpetual, exclusive, worldwide, royalty-free license,
with the right to sublicense, under the Joint Patents; and (ii) a perpetual, non-exclusive, royalty-free license to the Joint
Know-How, in each case solely to develop, make, have made, use, sell, offer for sale, have sold and import the Compound and Products
in the Field of Use, subject to the terms and conditions set forth below in subparagraph (c). TGTX shall provide to Rhizen when
enforcing any such rights under this Section 13.1(A)(b) reasonable assistance in such enforcement, at Rhizen’s request and
cost, including joining such action as a party plaintiff if required by applicable Law to pursue such action.

 

(c)
TGTX shall:

 

(i)
at no cost to Rhizen transfer to Rhizen as soon as reasonably practicable all Data and information in TGTX’s or its Affiliates’
Control and possession relating to the Compound or Products as may be necessary to enable Rhizen to practice such license,

(ii)
at no cost to Rhizen transfer and assign to Rhizen all of its right, title and interest in and to all INDs, NDAs, drug dossiers
and master files with respect to any and all Products and all regulatory approvals with respect to any and all Products, and

(iii)
Take such other commercially reasonable actions and shall execute such other instruments, assignments and documents as may be
necessary to effect the transfer of rights under this subparagraph (c) to Rhizen, including without limitation assignments of
any contracts, including sublicensing agreements, related to the Development and Commercialization of any Product or New Product,
unless such assignment is prohibited by a contract and the applicable consent cannot be reasonably procured at reasonable cost.
TGTX will use reasonable commercial efforts to obtain the consent of any third-party to any contract or agreement related to the
Development or Commercialization of the Product or a New Product, which consent is required for the assignment of any such contract
or agreement from TGTX to Rhizen, provided, however, that any cash payment required by TGTX in order to procure any such consent
shall be deemed not commercially reasonable. Prior to receipt of such consent, TGTX shall make available to Rhizen all rights
and other benefits of such contracts, on a subcontract or sublease basis or in some other appropriate manner to the fullest extent
reasonably practicable and permitted by the terms of the contract or otherwise consented to by the other party to such contract,
and Rhizen shall be considered an independent subcontractor or sublessee of TGTX, with respect to all matters concerning such
contracts.

 

(B) termination
of this Agreement by TGTX pursuant to Section 12.4:

 

(a)
the license granted by Rhizen to TGTX pursuant to Section 2.1 remains in full force and effect in accordance with its terms and
until such time on a country-by-country basis (i.e. partial) as the expiration of the Royalty Term or Entire territory , subject
to TGTX’s compliance with Article 6;

 (b)
all JSC participation rights of Rhizen shall terminate and be of no further force or effect;

 

    	36

    	 

    

  

(c)
pending the outcome of arbitration proceedings pursuant to Article 20, TGTX shall have the right to pay all amounts that become
due under Article 6 after such termination into an escrow account with a reputable bank, and to the extent the arbitrators award
damages to TGTX, the arbitrators shall be authorized, in their discretion, (i) to cause the release to TGTX of all or any part
of the escrowed funds in partial or full satisfaction of such award, and/or (ii) to adjust the amounts payable by TGTX to Rhizen
under this Agreement to compensate TGTX for damages suffered by TGTX as a result of Rhizen’ material breach.

 

(C)
termination of this Agreement by Rhizen pursuant to Section 12.3, or termination of this Agreement by Rhizen pursuant to Section
12.4 (subject to paragraph (b) thereof): 

 

(a)
The license granted by Rhizen to TGTX under Section 2.1 shall terminate and revert to Rhizen on the effective date of termination.

 

(b)
Rhizen shall have the right, exercisable upon written notice by Rhizen to TGTX given within sixty (60) days after the effective
date of such termination, to obtain, and effective upon such notice, TGTX shall, and it hereby does, grant to Rhizen, a perpetual,
exclusive, worldwide, royalty-bearing license, with the right to sublicense, under TGTX Intellectual Property Rights (which, for
purposes of this Section 13.1 shall not include the Joint Patents or the Joint Know-How) solely to develop, make, have made, use,
sell, offer for sale, have sold and import the Compound and Products in the Field of Use, subject to the terms and conditions
set forth below in subparagraph (c). TGTX shall provide to Rhizen when enforcing any such rights under this Section 13.1(C)(b)
reasonable assistance in such enforcement, at Rhizen’s request and cost, including joining such action as a party plaintiff
if required by applicable Law to pursue such action. In consideration for such exclusive license, Rhizen shall pay to TGTX a royalty
based on the fair market value of such license.  The royalty will be negotiated in good faith by the Parties within fifteen
(15) days following the effective date of the termination. If the Parties cannot agree on the terms of the royalty, the parties
will select a disinterested Third Party to determine the fair market value of the license (the “Appraiser”). 
Once the Appraiser is selected, the Appraiser shall be instructed to furnish a written appraisal within sixty (60) days of it
selection. TGTX shall bear the Appraiser’s reasonable costs and expenses.  The fair market value royalty will be paid
out of Rhizen’s gross profits following the first commercial sale of the Product, and which gross profits will be based
on all amounts paid to Rhizen from its sublicensing or from sales directly or indirectly in the particular country or Territory.
The term of such royalty will expire on the expiration of the last to expire issued Valid Claim within the TGTX Patents covering
the Product in the particular country or Territory.

 

TGTX
shall, and it hereby does, upon such Termination grant to Rhizen, (i) a perpetual, exclusive, worldwide, royalty-free license,
with the right to sublicense, under the Joint Patents; and (ii) a perpetual, non-exclusive, royalty-free license to the Joint
Know-How, in each case solely to develop, make, have made, use, sell, offer for sale, have sold and import the Compound and Products
in the Field of Use, subject to the terms and conditions set forth below in subparagraph (c). TGTX shall provide to Rhizen when
enforcing any such rights under this Section 13.1(C)(b) reasonable assistance in such enforcement, at Rhizen’s request and
cost, including joining such action as a party plaintiff if required by applicable Law to pursue such action.

 

    	37

    	 

    

  

(c)
TGTX shall:

 

(i)
at no cost to Rhizen , transfer to Rhizen as soon as reasonably practicable all Data and information in TGTX’s or its Affiliates’
Control and possession relating to the Compound or Products as may be necessary to enable Rhizen to practice such license.

(ii)
at no cost to Rhizen, transfer and assign to Rhizen all of its right, title and interest in and to all INDs, NDAs, drug dossiers
and master files with respect to any and all Products and all regulatory approvals with respect to any and all Products, and

(iii)
Take such other commercially reasonable actions and shall execute such other instruments, assignments and documents as may be
necessary to effect the transfer of rights under this subparagraph (c) to Rhizen, including without limitation assignments of
any contracts, including sublicensing agreements, related to the Development and Commercialization of any Product or New Product,
unless such assignment is prohibited by a contract and the applicable consent cannot be reasonably procured at reasonable cost.
TGTX shall use reasonable commercial efforts to obtain the consent of any third-party to any contract or agreement related to
the Development or Commercialization of the Product or a New Product, which consent is required for the assignment of any such
contract or agreement from TGTX to Rhizen, provided, however, that any cash payment required by TGTX in order to procure any such
consent shall be deemed not commercially reasonable. Prior to receipt of such consent, TGTX shall make available to Rhizen all
rights and other benefits of such contracts, on a subcontract or sublease basis or in some other appropriate manner to the fullest
extent reasonably practicable and permitted by the terms of the contract or as consented to by the other party to the contract,
and Rhizen shall be considered an independent subcontractor or sublessee of TGTX, with respect to all matters concerning such
contracts.

(d)
all JSC participation rights of TGTX shall terminate and be of no further force or effect;

(e)
pending the outcome of arbitration proceedings pursuant to Article 20, TGTX shall pay all amounts that become due under Article
6 after such termination into an escrow account with a reputable bank, and to the extent the arbitrators award damages to Rhizen,
the arbitrators shall be authorized, in their discretion, (i) to cause the release to Rhizen of all or any part of the escrowed
funds in partial or full satisfaction of such award, and/or (ii) to adjust the amounts payable to Rhizen under this Agreement
to compensate Rhizen for damages suffered by Rhizen as a result of TGTX’s material breach.

 

13.2 Any termination
of this Agreement shall be without prejudice to any rights or obligations which have accrued to any Party prior to such termination.
Without limiting the generality of the foregoing, termination of this Agreement shall not preclude either Party from claiming
any other damages, compensation or relief that it may be entitled to hereunder.

 

    	38

    	 

    

  

14 
FALLOW

 

14.1. If at
any time the development program has not made any significant progress during any 6 month period during the Term (prior to the
First Commercial Sale), the licensing shall be deemed to be fallow and liable to additional consequences. The JSC shall decide
whether TGTX has made significant progress pursuant to this Section 14.1, provided that if Rhizen disagrees with the determination
of the JSC, Rhizen may submit such dispute to an independent Third Party analyst pursuant to the process set forth in Section
3.2.5(a) hereof, and the decision of such analyst as to whether significant progress has been made shall be binding on the Parties.
On determination of such an event, the JSC may have an option to provide TGTX with an extension of 12 months if TGTX pays Rhizen
a maintenance fee. For the avoidance of doubt, the Development of a Product shall be considered as not making significant progress
under this Section 14.1 if the aggregate amount spent by TGTX or its Sublicensee(s) on the Development activities for each of
two consecutive three (3) month periods prior to the filing of an NDA is less than an amount to be specified by the Parties within
thirty (30) days following the effective date hereof, except in specific circumstances where such level of development expenses
is warranted, as mutually agreed by the Parties.

 

14.2. The Maintenance
Fee as per section 14.1 shall be calculated by the Parties in good faith considering the anticipated loss to Rhizen of various
milestone(s) & other payments (under Article 6 above) expected based on the then-current stage(s) of the Development Plan.

 

15 SURVIVING
PROVISIONS 

 

Sections 6.5
and Articles 1, 8, 9, 10, 13, 14, 15, 16, 18, 19, 20 and 22 shall survive termination or expiration of this Agreement. In addition,
if the license granted to TGTX under Section 2.1 survives termination as set forth in Section 13.3, Sections 6.3, 6.4 and 6.5
shall survive such termination.

 

16 NOTICES

 

Notices required
or permitted to be made or given to either Party hereto pursuant to this Agreement shall be sufficiently made or given on the
date of mailing if sent to such Party by certified or registered mail, postage prepaid, addressed to it at its address set forth
or to such other address as it shall designate in the course of this Agreement by written notice to the other Party as follows:

 

	If
    to Rhizen: 	If
    to TGTX: 
	  Rhizen	  TGTX. 
	 	 
	  Attention:
    	  Attention:  
	  Rhizen
    Pharmaceuticals S A	  TG Therapeutics,
    Inc.
	  Fritz-Courvoisier
    40,	  787 Seventh Avenue
	  CH-2300
    La Chaux-de-Fonds, 	  New York, NY 10019
	  Switzerland.	  U.S.A.
	  Email-
    us@rhizen.com 	  Email – hm@tgtxinc.com
	 	 

 

17 INDEPENDENT
CONTRACTOR 

 

The relationship
of TGTX and Rhizen under this Agreement is intended to be that of an independent contractor. Nothing contained in this Agreement
is intended or is to be construed so as to constitute the Parties as partners or joint ventures or either Party as an agent or
employee of the other. Neither Party has any express or implied right or authority under this Agreement to assume or create any
obligations on behalf of or in the name of the other, or to bind the other Party to any contract, agreement or undertaking with
any Third Party. 

 

    	39

    	 

    

 

 18 COMPLETE
AGREEMENT 

 

The Parties
hereto acknowledge that this Agreement sets forth the entire agreement and understanding of the Parties, and supersedes all prior
written or oral agreements or understandings with respect to the subject matter hereof, including JV Agreement, but excluding:

 

(a) that
certain Confidentiality Agreement between the Parties dated April 27, 2012 (the “Original Confidentiality Agreement”),
which shall remain in full force and effect in accordance with its terms; provided, however, that all “Confidential
Information” (as defined by the Original Confidentiality Agreement) of Rhizen relating to its single targeted Pi3K Delta
kinase Inhibitor programs, including, without limitation, RP5264, shall be deemed Confidential Information for purposes of this
Agreement; and

(b) In the
event of any conflict between the provisions of this Agreement and the provisions of the Original Confidentiality Agreement, this
Agreement shall control. No modification of this Agreement shall be deemed to be valid unless in writing and signed by both Parties

 

19 ASSIGNMENT

 

Except as expressly
provided hereunder, neither this Agreement nor any rights or obligations hereunder may be assigned or otherwise transferred by
either Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld); provided,
however, that either Party may assign this Agreement and its rights and obligations hereunder without the other Party’s
consent: (a) in connection with the transfer or sale of all or substantially all of the business of such Party to which this Agreement
relates to a Third Party, whether by merger, sale of stock, sale of assets or otherwise (each, a “Change of Control
Transaction”), provided that in the event of a Change of Control Transaction in which the acquiring party is a Third
Party, intellectual property rights of the acquiring party to such Change of Control Transaction that exist prior to the effective
time of such Change of Control Transaction shall not be included in the technology licensed hereunder or otherwise subject to
this Agreement; or (b) to an Affiliate, provided that no such assignment to an Affiliate shall relieve the assigning Party of
its obligations hereunder. The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the
benefit of the successors and permitted assigns of the Parties. Any assignment not in accordance with this Agreement shall be
void. 

 

20 GOVERNING
LAW AND DISPUTE RESOLUTION

 

		20.1	English
Language; Governing Law. This Agreement was prepared in the English language, which language shall govern the interpretation
of, and any dispute regarding, the terms of this Agreement.  This Agreement and all disputes arising out of or related to
this Agreement or any breach hereof shall be governed by and construed under the Laws of the State of New York without giving
effect to any choice of law principles that would require the application of the Laws of a different state.

		20.2	Disputes.

		(a)	The
                                         Parties recognize that disputes as to certain matters may from time to time arise during
                                         the Term which relate to either Party’s rights or obligations hereunder. 
                                         It is the objective of the Parties to establish procedures to facilitate the resolution
                                         of disputes arising under this Agreement in an expedient manner by mutual cooperation
                                         and without resort to litigation.  To accomplish this objective, the Parties agree
                                         to follow the procedures set forth in this Section 20.2 to resolve any controversy
                                         or claim arising out of, relating to or in connection with any provision of this Agreement,
                                         if and when a dispute arises under this Agreement.  With respect to all disputes
                                         arising between the Parties, including, without limitation, any alleged failure to perform,
                                         or breach, of this Agreement, or any issue relating to the interpretation or application
                                         of this Agreement, if the Parties are unable to resolve such dispute within sixty (60)
                                         days after such dispute is first identified by either Party in writing to the other,
                                         the Parties shall refer such dispute to the senior executive officers for each Party
                                         for attempted resolution by good faith negotiations within thirty (30) days after such
                                         notice is received.  If the senior executive officers designated by the Parties
                                         are not able to resolve such dispute within such thirty (30) day period, either Party
                                         may submit such dispute in accordance with Section 20.2(b).

 

    	40

    	 

    

  

		(b)	Arbitration.
                                         Any dispute arising out of or relating to this Agreement, including the breach, termination
                                         or validity thereof, which has not been resolved by the executives of the Parties as
                                         provided herein will be finally resolved by arbitration in accordance with the CPR Rules
                                         for Non-Administered Arbitration then currently in effect, by three arbitrators of whom
                                         each party will appoint one in accordance with the ‘screened’ appointment
                                         procedure provided in Rule 5.4, provided, however, that if one party fails to participate
                                         in either the negotiation or mediation as agreed herein, the other party can commence
                                         arbitration prior to the expiration of the time periods set forth above. The arbitration
                                         will be governed by the Federal Arbitration Act, 9 U.S.C. §§1 et seq., and
                                         judgment upon the award rendered by the arbitrator(s) may be entered by any court having
                                         jurisdiction thereof. The place of arbitration will be New York, NY. The award may be
                                         made a judgment by any court of competent jurisdiction pursuant to the New York Convention,
                                         9 U.S.C. § 201 et seq., and for this purpose the Party against whom the award is
                                         made will agree to the personal jurisdiction of the court in which recognition is sought
                                         and will not raise any argument of forum non conveniens.

		(c)	Notwithstanding
                                         anything to the contrary in this Article 20, either Party may seek injunctive relief
                                         in any court in any jurisdiction where appropriate.

 

21 FORCE MAJEURE

 

21.1 Neither
Party shall be liable for a failure to comply with a provision herein, if it is prevented from performing the said provision because
of force majeure, this notion being defined as an event beyond the control of the Parties and independent from their will including,
but not limited to, strikes or other labor trouble, war, insurrection, fire, flood, explosion, discontinuity in supply of power,
court order or governmental interference

 

21.2 Despite
the event of force majeure, either Party hereto shall undertake reasonable efforts to comply to the extent possible with its obligations
towards the other Party, pursuant to this Agreement.

 

21.3 The Party
invoking an event of force majeure shall notify it forthwith to the other Party, and must specify which one or ones of its obligations
it is being prevented from complying with, and the nature of force majeure, and must give an estimate of the period during which
it is likely that it shall be prevented from complying with the said obligation or obligations

 

    	41

    	 

    

  

22 MISCELLANEOUS

 

22.1 If any
provision of this Agreement should be or become fully or partly invalid or unenforceable for any reason whatsoever or should violate
any applicable law, this Agreement is to be considered divisible as to such provision and such provision is to be deemed deleted
from this Agreement, and the remainder of this Agreement shall be valid and binding as if such provision were not included therein.
There shall be substituted for any such provision deemed to be deleted a suitable provision which, as far as is legally possible,
comes nearest to the sense and purpose of the stricken provision

 

22.2 Failure
by any Party to enforce any term or provision of this Agreement in any specific instance or instances hereunder shall not constitute
a waiver by such Party of any such term or provision, and such Party may enforce such term or provision in any subsequent instance
without any limitation or penalty whatsoever.

 

22.3 This Agreement
is neither expressly nor impliedly made for the benefit of any entity other than the Parties.

 

22.4 The headings
set forth in this Agreement are for convenience only and do not qualify or affect the terms or conditions of this Agreement. Ambiguities
and uncertainties in this Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be
deemed to have caused the ambiguity or uncertainty to exist. This Agreement has been prepared in the English language, and the
English language shall control its interpretation. In addition, all notices required or permitted to be given hereunder, and all
written, electronic, oral or other communications between the Parties regarding this Agreement shall be in the English language.

 

22.5 No waiver
of any right or remedy hereunder shall be effective unless provided in writing executed by the waiving Party.

 

22.6 The agreement
survives in case either Party is acquired or goes bankrupt.

 

22.7 This Agreement
may be executed in one (1) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument. This Agreement shall be binding upon the delivery by each Party of an executed signature page to
the other Party by facsimile or electronic transmission. If signature pages are so delivered by facsimile or electronic transmission,
each Party shall also immediately deliver an executed original counterpart of this Agreement to the other Party by courier delivery
service. 

 

    	42

    	 

    

  

IN WITNESS WHEREOF,
the Parties have caused this Agreement to be executed by their duly authorized representatives as of the Effective Date

 

	TG THERAPEUTICS, INC.	 	RHIZEN Pharmaceutials SA
	 	 	 
	 	 	 
	Name: 	 	Name:
	Title 	 	Title:
	 	 	 
	Date:	 	Date:

 

    	43

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]